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ABSTRACT

Role of Mitochondria in TNF-alpha Neurotoxicity in Stroke

Danielle N. Doll

TNF-alpha is known to exacerbate infarct volume in animal models and elevated levels of TNFalpha are correlated with worse outcomes in stroke patients. However, the mechanism is not
well understood. TNF-alpha has been shown to be neurotoxic at high doses and after long
exposure times which is not clinically relevant. Thus, we show for the first time that TNF-alpha
at clinically relevant concentrations seen in the serum of stroke patients rapidly and profoundly
decreases mitochondrial function resulting in neuronal cell death through activation of caspase 8
and cytochrome c release. A slight decrease in mitochondrial function is detrimental to neurons
due to their high energy demand. Since TNF-alpha is known to be increased during ischemia
and correlated with negative outcomes, it is important to understand the neurotoxic mechanism
of TNF-alpha to develop potential therapeutic targets for stroke. Moreover, TNF-alpha is
increased during infections, and 30-40% of strokes occur during an active infection. We show
that having a stroke during an active bacterial infection mimic results in an increased infarct
volume, worsened neurological deficits, and prolonged sickness behavior. TNF-alpha’s rapid
and profound effect on mitochondrial function may be one mechanism by which stroke severity
is exacerbated, neurological deficits are worsened, and recovery delayed. Thus, enhancing
mitochondrial function acutely post-stroke could be a potential therapeutic intervention.
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Chapter 1
Introduction

1

1.1. Introduction on Stroke
Approximately 800,000 Americans suffer from a stroke each year, and the American Heart
Association predicts a 5.1 percent increase in stroke cases for Americans between 45 and 64
years of age by 2030. More than 137,000 people die from a stroke each year resulting in stroke
being the fifth leading cause of death and leading cause of disability in the United States
(American Heart Association, 2012). Ischemic strokes which result from an interruption of
blood flow to the brain due to a clot, account for 87 percent of all stroke cases (American Heart
Association, 2012). Although ischemic stroke is a devastating problem in the United States and
worldwide, the only FDA approved treatment is tissue plasminogen activator (tPA), which is a
thrombolytic to break up the clot. Unfortunately, less than 5 percent of patients receive tPA due
to its limited time window of 4.5 hours; thus, most patients only receive supportive care
(Fonarow et al., 2011).

An occlusion of a cerebral artery causes deprivation of oxygen, glucose, and lipids resulting in
necrotic brain tissue. Breakdown of the blood-brain barrier and activation of inflammatory cells
in the brain and in the periphery result in inflammation in the necrotic tissue (Davies et al., 1999;
Zheng and Yenari, 2004). Inflammatory mechanisms both in the periphery and in the central
nervous system (CNS) are important in promoting brain inflammation by producing
inflammatory mediators such as cytokines and clearing away dead tissue after cerebral ischemia
(Danton and Dietrich, 2003). Cytokines are key players in the inflammatory mechanism and
contribute to the progression of ischemic damage (Liu et al., 1994). The discovery of
biomarkers and novel therapeutics for stroke has been the focus of extensive research recently;
thus, understanding the roles of pro-inflammatory and anti-inflammatory cytokines that are
produced during stroke will help us further understand how inflammation contributes to the
2

progression of ischemic damage and provide potential targets for novel therapeutics and
biomarkers for prognosis of stroke.

1.2. Stroke, Aging, and Immune System
It was once thought that the brain was an immune-privileged organ and did not produce an
inflammatory response to ischemic brain injury (Arvin et al., 1996). However, it is now well
established that cells in the brain produce and secrete cytokines, chemokines and adhesion
molecules enabling the brain to mount a central and peripheral inflammatory response to
ischemia (Liu et al., 1994; Ferrarese et al., 1999). Both central and peripheral inflammation are
key contributors to the pathophysiology of stroke (Dirnagl et al., 1999; Wang et al., 2007a).
There is increasing evidence that peripheral inflammation not only plays a role in the pathology
of stroke but impacts stroke etiology by increasing susceptibility (Emsley and Hopkins, 2008).
Risk factors such as atherosclerosis, obesity, diabetes, and hypertension are all associated with
an increased peripheral inflammatory profile, and the majority of stroke patients have at least
one of these risk factors (Hankey, 2006). Many of these factors could participate in regulating
interactions between the central and peripheral immune systems; those classically identified as
immune response mediators and those traditionally unassociated. A further understanding of the
interaction between the immune and nervous system is important to determine the contribution
of mal-adaptive immune responses as a causative factor resulting in poor functional outcome.

Stroke most commonly occurs when an atherosclerotic plaque ruptures resulting in
thromboembolism. The initiation and progression of plaques are driven by inflammatory cells
and mediators such as cytokines and chemokines (Hansson and Libby, 2006). Dysfunctional
endothelial cells of the vascular wall at the site of the atherosclerotic lesion express adhesion
3

molecules such as VCAM-1 and ICAM-1 that recruit macrophages and T cells (Cybulsky et al.,
2001). These immune cells produce cytokines and chemokines along with vasoactive molecules
that activates immune cells and smooth muscle cell proliferation resulting in the progression of
the atherosclerotic lesion (McColl et al., 2009). The continuous recruitment of immune cells and
activation results in the formation of a mature plaque, and activated macrophages and T cells are
significant part of the plaque (Zhou et al., 2000). These activated immune cells secrete matrix
metalloproteinases (MMPs) which are collagen-degrading proteases that destabilize the plaque
and results in the rupture of the plaque causing ischemia (Johnson et al., 2005). It is clear that
inflammation is an essential contributor to the development and progression of atherosclerosis,
and numerous pre-clinical studies show that animal models deficient in adhesion molecules,
inflammatory mediators, and T cells attenuate the progression of plaque formation and the
instability of the plaque (Boring et al., 1998; Dong et al., 2000; Zhou et al., 2000; Chi et al.,
2004). Clinical studies using positron emission tomography (PET) have shown patients
presenting with transient ischemic attack have high 18F-fluoreodeoxyglucose (FDG) signal in
atherosclerotic plaques (Rudd et al., 2002; Davies et al., 2005). FDG is taken up by
macrophages and indicates the degree of macrophage activation, which further supports
inflammation causing plaque instability (Warburton and Gillard, 2006).

Increased atherosclerotic burden is a hallmark of obesity and diabetes, and these co-morbid
diseases cause endothelial dysfunction through insulin resistance and inflammation (Hunt and
Jurd, 1997). Thus, risk factors such as obesity and diabetes increase stroke susceptibility
through pro-atherogenic effects. Furthermore, clinical studies have linked peripheral bacterial
infections and increased stroke susceptibility during the first 3 days after infection (Grau et al.,
1998; Smeeth et al., 2004). Infection is known to increase vascular disease, along with
4

increasing inflammatory mediators such as cytokines to clear the infection, which can promote
the formation of plaques and increase destabilization of the plaque (Li et al., 2002; Michelsen et
al., 2004). Along with pro-atherogenic effects of infection, infection promotes a
hypercoagulable state (Vila et al., 2000b). Interleukin (IL)-6 and tumor necrosis factor-α (TNFα) are cytokines increased during the inflammatory response to infection that activate the tissue
factor-mediated extrinsic pathway of coagulation, and clinical studies have observed in stroke
patients with infections, increased platelet activation and decreased concentrations of anticoagulatory molecules such anti-thrombin, activated protein C, and free protein S (van der Poll
et al., 1990; van der Poll et al., 1994) Pre-clinical studies confirm these findings and
demonstrate that systemic administration of pro-inflammatory cytokines mimic characteristics of
infection. Obese animal models and animal models with other co-morbid diseases such as
diabetic mice and spontaneously hypertensive rats exhibit larger infarcts and more severe
neurological deficits (McGill et al., 2005; Terao et al., 2008). These pre-clinical and clinical
studies support the significance of peripheral inflammation and its impact on stroke and
demonstrate how the interaction between the immune system and the brain can affect
neurological dysfunction after an ischemic insult.

Not only does acute and chronic inflammation preceding stroke increase susceptibility to stroke
and increase brain damage after stroke, but stroke itself initiates a local inflammatory response
in the brain and peripheral inflammation that can amplify this central inflammatory reaction.
Interruption of cerebral blood flow results in the deprivation of oxygen, glucose, and other
essential nutrients to the brain and leads to a complex, multifaceted cascade of inflammatory
events.

5

It is evident that stroke is a vascular disease that results in neurological deficits after an ischemic
insult, and it is not surprising that the prevalence of stroke increases with age because aging
affects the vasculature and the immune system. Capillary networks and density decrease during
aging in the cortex of adult humans and animals (Brown et al., 2007b; Brown and Thore, 2011).
Chronic inflammation and acute infection contribute to capillary disruption and cell loss
resulting in a leaky BBB, and aged rodents exhibit increased BBB disruption along with reduced
neurogenesis after stroke (Darsalia et al., 2005; DiNapoli et al., 2008; Ingraham et al., 2008). In
addition, age-associated immune system dysfunction increases incidence of acute infections, and
co-morbid factors characterized by inflammation such as diabetes and atherosclerosis, and as
discussed above, these co-morbid factors greatly increase susceptibility to stroke and worsen
outcome after stroke (Castelo-Branco and Soveral, 2014).

Aged individuals are in a chronic state of low grade inflammation referred to as inflamm-aging,
and during inflamm-aging there is a shift in cytokines toward a pro-inflammatory state
producing pro-inflammatory cytokines such as TNF-α and IL-1 (Bruunsgaard et al., 1999;
Griffin, 2006). The immune dysregulation theory supports the idea that during healthy aging
anti-inflammatory mediators such as IL-10 inhibits the pro-inflammatory state; however,
individuals’ systems that are challenged with acute infections, co-morbid factors, genetic
predisposition, and environmental factors are unable to mount an anti-inflammatory response to
the shift in a pro-inflammatory state resulting in an increase incidence of infections, co-morbid
diseases, and stroke (Lio et al., 2004; Castelo-Branco and Soveral, 2014). Thus, understanding
the effect of age alone on stroke is difficult because it is likely that age is a surrogate for
increased chronic inflammation associated with co-morbid diseases. This creates a pro-
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atherogenic and pro-coagulable state responsible for the increased incidence of stroke in the
aged.

1.3. Immune Response to Stroke
The complex, multifaceted cascade of events that results from brain deprivation of oxygen,
glucose, and other essential nutrients to the brain causes dysfunction of the neurovascular unit
(del Zoppo, 2006). Acutely after ischemia, microglia are activated due to the increase in
extracellular ATP from the depolarization of neurons and glia, and activated microglia secrete
cytokines and chemokines along with developing phagocytic properties (Melani et al., 2005).
Within 4-6 hours after an ischemic insult, peripheral leukocytes migrate and adhere to vessel
walls and infiltrate into the ischemic brain tissue producing deleterious inflammatory mediators
(Wang et al., 2007a). Numerous studies have shown that neutrophils are the first blood-derived
cells from the periphery to infiltrate ischemic brain tissue, and when neutrophil infiltration is
inhibited, infarct size is significantly decreased (Chopp et al., 1996; Hallenbeck, 1996; Yenari et
al., 1998). Reperfusion of the occluded vessel generates reactive oxygen species (ROS)
resulting in further activation of immune and brain cells and oxidative stress, and these activated
cells secrete cytokines, chemokines, MMPs, nitric oxide (NO), more ROS, and adhesion
molecules that increase cell death and disruption of the blood-brain barrier (BBB) (Coyle and
Puttfarcken, 1993; Melani et al., 2005). Moreover, reperfusion and disruption of the BBB leads
to further leukocyte infiltration into the brain amplifying the inflammatory response and
enhancing damage. The peripheral and central inflammatory response after ischemia leads to an
increase in neuronal death, infarct size, and severity of stroke.

7

Adhesion molecules are essential for leukocytes to infiltrate into the brain after stroke, and
notably ICAM-1 and VCAM-1, the same adhesion molecules that recruit immune cells to
atherosclerotic lesions, mediate the interaction between leukocytes and the vascular endothelium
(DeGraba, 1998). Furthermore, both ICAM-1 and VCAM-1 expression increases after
stimulation by cytokines such as TNF-α and IL-1 which are increased after stroke and in obese,
diabetic, and atherosclerotic patients (Wang et al., 2007a). An experimental stroke study in
diabetic rats showed higher expression of ICAM-1 in diabetic rats after stroke compared to nondiabetic rats, and this increase in adhesion molecules due to co-morbid diseases and infection
could contribute to the exacerbation of stroke and increase susceptibility to stroke (Ding et al.,
2005). Moreover, using ICAM-1 deficient mice and inhibiting ICAM-1 and VCAM-1in
experimental stroke studies result in smaller infarct sizes, and clinically increased plasma and
cerebral spinal fluid levels of ICAM-1 and VCAM-1 are observed in stroke patients and
correlated with stroke severity (Connolly et al., 1996; Kitagawa et al., 1998; Selakovic et al.,
2003; Ehrensperger et al., 2005). Thus, peripheral inflammation due to infection or other comorbid factors may increase stroke severity and stroke susceptibility by increasing adhesion
molecules and other inflammatory mediators that produce an environment that enhances
leukocyte activation and adhesion.

Furthermore, brain and immune cells produce reactive oxygen species (ROS), and restoration of
blood flow in the occluded vessel generates additional ROS (Coyle and Puttfarcken, 1993).
ROS activate endothelial cells and cause oxidative stress (Melani et al., 2005; Schock et al.,
2007). Oxidative stress and the induction of the inflammatory cascade leads to the breakdown
of the blood-brain barrier allowing activated blood-borne immune cells such as neutrophils and
T-cells to infiltrate and accumulate in the ischemic brain tissue (Melani et al., 2005). Along with
8

the accumulation of activated immune cells from the periphery, microglia in the brain become
activated after cerebral ischemia due to the increase in extracellular ATP from the depolarization
of neurons and glia and the release through damaged plasma membranes of dying cells (Melani
et al., 2005). Activated microglia secrete pro-inflammatory mediators such as cytokines and
develop phagocytic and major histocompatibility complex (MHC) class II-restricted antigen
presenting characteristics (Davalos et al., 2005). Microglia activation can be beneficial by
producing growth factors such as brain-derived neurotrophic factor and clearing away dead
tissue and debris after ischemia; however, the release of pro-inflammatory cytokines such as
tumor necrosis factor-α (TNF-α) and production of reactive oxygen species and nitric oxide after
microglia activation is detrimental (Cardenas et al., 2002; Tang et al., 2007). ATP is an early
danger signal increasing inflammation, but as cells die, molecular signals called danger
associated molecular pattern molecules (DAMPs) are generated and activate pattern recognition
receptors such as toll like receptors (TLRs) (Marsh et al., 2009). These pattern recognition
receptors are found on endothelial cells and microglia in the brain along with infiltrating
leukocytes from the periphery, and activation of pattern recognition receptors increases
cytokines (Marsh et al., 2009). Moreover as neurons begin to die after ischemia, cell-cell
interactions with microglia are lost and further increases inflammatory signaling (Matsumoto et
al., 2007). Thus acutely after ischemia, hypoxia and oxidative stress induces synthesis of
nuclear factor κB (NF-κB), hypoxia inducible factor 1 and many other transcription factors that
increase the expression of pro-inflammatory and anti-inflammatory cytokines (Baeuerle and
Henkel, 1994). As cells die and brain tissue is damaged, molecular danger signals further
potentiate the inflammatory response by activating more microglia and infiltrating leukocytes in
a feed-forward response producing more deleterious pro-inflammatory cytokines. This increase
in expression of cytokines further increases the expression of adhesion molecules on endothelial
9

cells that result in additional recruitment of leukocytes from the periphery (Bargatze et al.,
1994). These inflammatory changes after ischemia lead to an increase in neuronal cell death
resulting in a larger infract volume and worse outcome. Inflammation is a key player in brain
damage during cerebral ischemia; however, inflammation aiding in repair and recovery after
cerebral ischemia can be beneficial. Thus, further mechanistic understanding of how
inflammation contributes to injury or repair after ischemia is important for discovering potential
therapeutic targets for stroke and for using inflammatory mediators such as cytokines as
biomarkers for prognosis.

1.4. Mitochondria
The brain represents only 2% of the body mass, but consumes >20% of O2 and glucose (Mink et
al., 1981); the result of the high energy demand of neurons to maintain ion gradients (Attwell
and Laughlin, 2001; Howarth et al., 2010; Harris and Attwell, 2012) and the almost exclusive
use of mitochondrial oxidative phosphorylation for the production of ATP (Mergenthaler et al.,
2013). As such, even transient reductions in O2 or glucose put neurons at risk of dysfunction and
death.

During aging (Harman, 1972; Navarro et al., 2002), brain mitochondrial function is
compromised, expressed as a reduction in oxidative phosphorylation (OxPhos), transport of
mitochondria from soma to energy demanding synapses and excessive mitochondrial fission
(Chaturvedi and Flint Beal, 2013). Thus normal aging sets the stage for limited mitochondrial
response to ischemia. These mitochondrial defects could be responsible for the increase in the
prevalence of stroke, increase in severity of infarcts and the limited recovery from stroke with
advancing age.
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With age, the brain experiences a reduced capacity to take up and utilize glucose as an energy
source (Mink et al., 1981). This reduction in glucose utilization in the face of persistent energy
demand means that the brain must tap into other sources of energy to supply its basic functions
and to respond to ischemic events. In the absence of glucose, brain mitochondria use ketone
bodies derived from endogenous sources or dietary lipids through β-oxidation to supply carbon
fragments for OxPhos (Cahill, 2006). Inasmuch normal aging compromises mitochondrial
structure, function and movement, the possibility is strong that progressive mitochondrial defects
contribute to the age-related increase in stroke prevalence, severity and lack of recovery.

Several neurological diseases such as multiple sclerosis, Parkinson’s disease, and Alzheimer’s
disease have a common pathological finding of neuroinflammation (Di Filippo et al., 2010).
Moreover, it is well accepted during the pathogenesis of both inflammatory and
neurodegenerative CNS disorders mitochondria are crucial players. Because neurons are in high
energy demand, and a slight decline in ATP production results in increased susceptibility to
death leads to the hypothesis that mitochondrial dysfunction may be the link between
neuroinflammation and neuronal degeneration.

Indeed, mitochondria can be the switch for the

initiation of apoptosis through the opening of mitochondrial permeability transition pores
(mtPTP) resulting in the dissipation of the mitochondrial inner membrane potential.

This

dissipation of mitochondrial inner membrane potential causes the release of several molecules
that activate caspases leading to apoptosis. Several cytokines, including TNF-α, are known to
affect mitochondrial function in non-neuronal cells; however, the cytokine-induced neuronal
mitochondrial dysfunction still remains controversial. Although it is believed that an acute
neuroinflammation may be beneficial to the CNS through preconditioning to prevent further
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damage to the neurons, chronic inflammation may represent a self-perpetuating detrimental
response after an initial insult such as stroke.

Further, the extent to which factors known to increase risk of stroke do so by decreasing
mitochondrial function is a challenge to the field of stroke research. Dysregulated inflammation
is associated with many of the risk factors associated with stroke such as hypertension, diabetes
and obesity (Smith et al., 2013). An elevated systemic inflammatory profile is associated with
atherosclerosis, hypertension, diabetes, obesity, and peripheral infection. Thus far, studies have
provided evidence that the release of oxidants, proteolytic enzymes and inflammatory cytokines
alter blood brain barrier (BBB) permeability. The BBB excludes the majority of bacteria;
however, similar to ischemia and reperfusion, inflammation induced by bacteria alters BBB
permeability. Thus, understanding the effect of inflammation on mitochondrial function is
important for increasing our understanding of how inflammation post-stroke can increase
neurons susceptibility to death resulting in increased infarct size and poor outcome, and how
inflammation plays a role in increasing the susceptibility to stroke.

Finally, methods of

enhancing mitochondrial functions as a therapeutic target to prevent, treat and recover from
stroke have not yet been explored.

1.5. Cytokine Changes Following Stroke
Cytokines are soluble glycoproteins that are produced by cells in the brain in response to
damaged tissue after ischemia and are responsible for regulating the innate and adaptive immune
response (Ferrarese et al., 1999). Microglia, astrocytes, endothelial cells, and neurons in the
brain are able to secrete pro-inflammatory and anti-inflammatory cytokines (Ferrarese et al.,
1999). An increase in production of pro-inflammatory cytokines and a decrease in production of
12

anti-inflammatory cytokines is correlated with a larger infarct size in animal models and a worse
clinical outcome (Vila et al., 2003). TNF-α, interleukin (IL)-1β, IL-6, and IL-10 are
inflammatory cytokines that have been found to be related to ischemic stroke and have been
implicated as therapeutic targets and biomarkers for prognosis. The inflammatory response to
ischemia changes with time, and knowing the timing of when these cytokines are increased or
decreased and how these cytokines affect infarct volume is important in understanding how
cytokines can be utilized clinically. TNF-α and IL-1β are well characterized in experimental
stroke studies and human subjects. However, little is known about the temporal profile of IL-6
and IL-10, and fewer experimental stroke investigations have studied IL-6.

A. TNF-α
Tumor necrosis factor-alpha (TNF-α) precursor is membrane bound and cleaved by TNF-α
converting enzyme (TACE) to release the soluble form that can bind to TNFR1 or TNFR2 (Liu
et al., 1996). Most cells in the brain express TNFR1, and TNFR1 has an intracellular death
domain (DD) with which adaptor proteins such as TNFR-associated DD protein (TRADD)
interacts, and the interaction of TRADD with the intracellular DD of TNFR1 elicits signaling for
cell death or cell survival by recruiting other adaptor proteins (Liu et al., 1996; Gourin and
Shackford, 1997; Chan et al., 2000). The recruitment of adaptor proteins such as caspase-8 and
FAS-associating protein with a death domain (FADD) result in apoptosis, and recruitment of
TNF-receptor associating factor 2 (TRAF2) and receptor-interacting protein (RIP) activate NFκB resulting in activation of genes for anti-inflammatory, anti-apoptotic proteins along with proinflammatory, apoptotic, and cytotoxic proteins (Gourin and Shackford, 1997). Therefore, the
structure of the TNF-signaling complex enables TNF-α to induce inflammation and cell death
after stroke or induce tolerance to ischemia.
13

Experimental Stroke Studies
Consequently in experimental stroke studies, it is not surprising that TNF-α has been shown to
exacerbate infarct size and be neuroprotective. In a mouse distal permanent middle cerebral
artery occlusion (pMCAO) electrocoagulation ischemic model, intracisternal injection of TNF-α
48 hours before occlusion decreases infarct volume (Nawashiro et al., 1997c). Furthermore,
using the same ischemia model TNF-α, TNFR1, and TNFR2 knock-out mice show larger infarct
size compared to control mice suggesting that TNF-α is neuroprotective (Lambertsen et al.,
2009). However, multiple approaches suggest that TNF-α is neurotoxic in stroke. I.p. or i.v.
injection of TNF-α binding protein immediately after occlusion and topical administration of
TNF-α binding protein immediately and 1 hour after occlusion in the distal pMCAO
electrocoagulation ischemic model causes a dose-dependent decrease in infarct volume at 1
hour, 24 hours, and 2 weeks (Nawashiro et al., 1997a, b). Also, in the one hour distal transient
middle cerebral artery occlusion (tMCAO) filament ischemia mouse model, i.c.v. injection of
anti-TNF antibody decreases infarct size (Yang et al., 1999). In the rat ischemia model using the
distal tMCAO and distal pMCAO where the vessel is occluded and cut, treating with TNF-α 24
hours before occlusion is neurotoxic and increases infarct volume (Barone et al., 1997). Also, in
the distal pMCAO thromboembolic model, inhibiting TACE decreases infarct volume. In
agreement with the mouse model, administrating anti-TNF antibody and TNF-α binding protein
in the rat ischemia model decreases infarct volume (Dawson et al., 1996; Lavine et al., 1998).
The neurotoxic versus neuroprotective action of TNF-α is most likely due to signaling through
nuclear factor κB producing both pro-inflammatory and anti-inflammatory mediators and the
timing of administration of TNF-α in experimental stroke models.

14

Time Course in Experimental Stroke Studies
After stroke onset, TNF-α mRNA expression is induced within thirty minutes after both tMCAO
and pMCAO in mice and rats, and TNF-α protein expression is seen within 1 hour in the cortex
and striatum after tMCAO in spontaneously hypertensive rats (Liu et al., 1994). Levels of TNFα mRNA and protein peak between 12 and 24 hours in both mice and rats and remain elevated
up to 10 days in mice and 6 days in rats (Buttini et al., 1996; Gregersen et al., 2000). The timing
of the expression of TNF-α after ischemia is found to be comparable among different mouse
strains after pMCAO, but the level of expression is different (Lambertsen et al., 2002). Cells
producing TNF-α are found at 12 and 24 hours after stroke in the penumbra of all mouse strains
(Lambertsen et al., 2002). Interpretation of the time course of TNF-α is complicated in animal
models because of the use of different strains of mice and rats, different methods for measuring
levels of TNF-α, and the time after stroke when levels are measured.

Time Course in Human Studies
In postmortem brain tissue studies, TNF-α positive cells are observed in all ischemic brains of
severe patients 3 days post-stroke and are present up to 15 months post-stroke, and the majority
of TNF-α positive cells are microglia and macrophages (Tarkowski et al., 1997; Dziewulska and
Mossakowski, 2003). TNF-α positive neurons peak between 2 and 3 days post-stroke, TNF-α
positive infiltrating immune cells from the periphery peak at day 3, and TNF-α positive
astrocytes peak from 15 hours to 14 days (Sairanen et al., 2001). Furthermore, TNF-α levels
have been measured in CSF at 0, 3, 7, 9, 21, 26 days and 3 months after stroke, and TNF-α
levels are only increased in stroke patients with white matter damage compared to normal
controls at 3 months post-stroke (Tarkowski et al., 1997). However, other studies have shown
that TNF-α levels are increased within 24 hours in the CSF (Vila et al., 2000a; Zaremba and
15

Losy, 2001). Studies assessing TNF-α in serum of stroke patients have not been conclusive. A
few studies found that serum TNF-α levels are not increased at admission or any time between
12 hours and 10 days after stroke (Fassbender et al., 1994; Montaner et al., 2003; Ormstad et al.,
2011b). In contrast, other studies have shown that TNF-α is increased in the serum of stroke
patients compared to controls within 6 hours and stay elevated for 10 days post-stroke (Zaremba
and Losy, 2001; Intiso et al., 2003). Moreover, studies measuring TNF-α in plasma observed a
significant increase of TNF-α in stroke patients at admission and within 24 hours post-stroke
(Vila et al., 2000a; Castellanos et al., 2002). The time after stroke when levels of TNF-α are
measured is critical and a contributing factor to the difference in results among and between
animal and human studies. Additionally, the severity of stroke may be a key factor in the timing
and magnitude of the increase in TNF-α.

B. IL1-β
IL1-β mRNA and protein is constitutively expressed in the brain at low levels and is regulated
by transcription, translation, cleavage and cellular release. IL1-β is synthesized as a large
precursor protein and is biologically inactive until it is cleaved by caspase-1 and secreted
(Thornberry et al., 1992). Once it is biologically active, it binds to type 1 IL-1 receptor (IL-1R1)
which associates with IL-1-receptor accessory protein (IL-1RAcP) that initiates intracellular
signaling (Korherr et al., 1997). IL1-β can also bind to IL-1R2, but IL-1R2 does not initiate
downstream signaling because IL-1R2 does not have an intracellular-signaling domain
(Thornberry et al., 1992; Korherr et al., 1997). Furthermore, IL-1R1 and IL-1R2 can exist in
soluble forms when they are shed from cell membranes (Thornberry et al., 1992; Korherr et al.,
1997; Allan et al., 2005). IL-1R2 and the soluble forms of both receptors act as decoy receptors
that prevent a ligand from initiating signaling pathways (Allan et al., 2005). During acute
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ischemia, there is an increase in ATP which promotes the cleavage and cellular release of IL1-β
(Thornberry et al., 1992). An increase in IL1-β can cause an increase in calcium entry through
NMDA-receptor ion channels resulting in neuronal cell death (Viviani et al., 2003).
Furthermore, IL1-β can potentiate inflammation by activating microglia, and IL1-β increases
leukocyte infiltration by increasing the expression of adhesion molecules on endothelial cells
and causing breakdown of the blood brain barrier contributing to an increased infarct size and
poor clinical outcome (Bernardes-Silva et al., 2001; Konsman et al., 2004; Mazzotta et al.,
2004).

Experimental Stroke Studies
Numerous studies have shown IL1-β to be neurotoxic in animal ischemia models. In the mouse
distal electrocoagulation pMCAO model, injecting an IL-1 receptor antagonist immediately and
4 hours after stroke decreases infarct volume (Nawashiro et al., 1997b). Moreover in the
proximal tMCAO filament model, treating with caspase-1 inhibitors 15 minutes before and
immediately after stroke decreased infarct volume, and using caspase-1 knock-out mice result in
smaller infarct volume compared to control mice (Hara et al., 1997a; Hara et al., 1997b). IL1-αβ
knock-out mice also show smaller infarct volumes (Ohtaki et al., 2003). Similarly, the rat
proximal electrocoagulation and filament pMCAO model exhibit an increase in infarct size in
animals treated with IL1-β 30 minutes before and after stroke and a smaller infarct size,
improved neurological score, and decreased number of leukocytes in the ischemic tissue when
treated with an IL-1 receptor antagonist at the time of occlusion along with injections at 4, 8, 12,
and 18 hours after stroke (Garcia et al., 1995; Loddick and Rothwell, 1996; Relton et al., 1996).
Proximal tMCAO filament models further shows IL1-β neurotoxicity, confirming what was seen
in the rat pMCAO and mouse ischemia models. Caspase-1 inhibitors decrease infarct volume in
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the tMCAO filament model when injected 15 minutes before surgery and after reperfusion, and
injecting IL1-β after reperfusion increases infarct size and brain edema (Yamasaki et al., 1995;
Hara et al., 1997b). IL-1β is a potent pro-inflammatory cytokine and has a role in activation of
numerous inflammatory processes. Using different ischemia models and different treatments to
enhance or inhibit IL-1β has resulted in the observation that IL-1β is constantly neurotoxic in
experimental stroke models.

Time Course in Experimental Stroke Studies
IL1-β positive microglia cells are found in the cortex 6 to 24 hours after stroke and elevated IL1β mRNA levels are observed at 10 hours in the brain tissue in both the proximal pMCAO and
proximal tMCAO filament mouse model (Hill et al., 1999; Clausen et al., 2008). However,
levels of IL1-β mRNA peak later at 18 hours in the pMCAO model compared to peak levels at
10 hours in the tMCAO model. In rat ischemia models, peak levels of IL1-β mRNA are seen at
6 hours in the proximal tMCAO and distal pMCAO suture model (Wang et al., 1994; Berti et al.,
2002) and elevated levels are seen as early as 1 hour after stroke (Liu et al., 1993; Wang et al.,
1994). Thus, both rat and mouse ischemia models show an early increase in expression of IL-1β
with peak expression dependent on the occlusion model used. Reperfusion allows for increased
access of leukocytes to the brain which may contribute to levels of expression peaking earlier in
the tMCAO model.

Time Course in Human Studies
IL1-β is elevated in the CSF of severe stroke patients with peak levels at 2-3 days post-stroke
(Tarkowski et al., 1995, 1997). However another study showed, IL1-β in CSF was elevated
within 6 hours after stroke regardless of its severity (Beridze et al., 2011). Two peripheral blood
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studies found elevated levels of IL1-β in plasma and serum of stroke patients (Mazzotta et al.,
2004; Sotgiu et al., 2006). However, all other studies showed no increase of IL1-β in serum or
plasma (Fassbender et al., 1994; Tarkowski et al., 1995; Ormstad et al., 2011b). IL-1β has a
highly localized role at the site of inflammation, and this localized role may be why IL-1β is not
seen in plasma or serum of stroke patients. However, soluble IL-1 receptor decoys are elevated
in plasma very early after stroke onset, which suggests an early attempt to regulate IL-1β
supporting the important role IL-1β plays in stroke (Emsley et al., 2007).

C. IL-6
IL-6 is an inflammatory cytokine that binds to class I cytokine receptors (Erta et al., 2012).
Class I cytokine receptors do not have intrinsic enzyme activity; thus, IL-6 signaling through its
class I cytokine receptor requires recruitment of an additional receptor protein gp130 (Saito et
al., 1992). IL-6 signaling activates intracellular tyrosin-kinases such as Janus Kinase (JAK)
which activates signal transducer and activator of transcription (STAT) family of transcription
factors and RAS-RAF-MAPK pathways (Erta et al., 2012). These transcription factors and
pathways can increase astrogliosis and angiogenesis which are important for tissue remodeling
and recovery after stroke (Tancredi et al., 2000; Hakkoum et al., 2007). Furthermore, IL-6 can
inhibit TNF-α, induce apoptosis in neutrophils, and recruit monocytes and T-cells causing the
transition between innate and adaptive immune response (Marz et al., 1996). However, IL-6 can
be detrimental by increasing body temperature which has been shown to increase brain damage
after stroke (Azzimondi et al., 1995).
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Experimental Stroke Studies
Few studies have been completed that assess IL-6 and stroke. IL-6 knock-out mice do not show
a difference in infarct size compared to wild types mice in the proximal tMCAO filament model
(Clark et al., 2000). However, when body temperature of IL-6 knock-out mice is controlled to
levels of wild type mice, IL-6 knock-out mice exhibit larger infarcts suggesting IL-6 is
neuroprotective (Herrmann et al., 2003). This finding is consistent with the proximal pMCAO
electrocoagulation rat model in which IL-6 was injected 30 minutes before and 15 minutes after
pMCAO and infarct size was reduced (Loddick et al., 1998).

Time Course in Experimental Stroke Studies
IL-6 is elevated as early as 3-3.5 hours post-stroke and peaks between 6 and 24 hours depending
on the ischemia model. In both mouse proximal pMCAO and tMCAO filament model, levels of
IL-6 mRNA are elevated at 10 hours and peak expression is at 18 hours. In rat proximal
tMCAO models, elevated IL-6 mRNA and protein levels are seen 3-3.5 hours after stroke and
peak expression of IL-6 protein at 12 and 24 hours (Wang et al., 1995; Suzuki et al., 1999).

Time Course in Human Studies
CSF IL-6 is elevated in stroke patients and increases within 24 hours and peaks 2-3 days after
stroke (Tarkowski et al., 1995, 1997). Vila et al. (2000a) and Beridze et al. (2011) found that
CSF IL-6 levels are elevated but only in severe stroke patients. Furthermore, IL-6 is elevated in
serum and plasma during the first week after stroke in all published studies. However, some
studies show IL-6 levels peaking at 10 hours in serum while other studies show levels of IL-6
peaking between 3 and 7 days after stroke (Fassbender et al., 1994; Perini et al., 2001; WajeAndreassen et al., 2005). Thus, there is agreement that IL-6 is elevated in stroke patients during
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the week after stroke onset. However, the timing at which IL-6 levels peak appear to depend on
stroke severity and stroke type.

D. IL-10
IL-10 is an anti-inflammatory cytokine that signals through the IL-10 receptor complex,
composed of two chains of IL-10R1 and two chains of IL-10R2 (Krause et al., 2002). The two
chains of IL-10R1 bind IL-10 and IL-10R2 initiates signal transduction. Jak1 is constitutively
bound to IL-10R1 and Tyk2 is constitutively bound to IL-10R2, and when the IL-10 receptor
complex is activated by IL-10, two tyrosine residues on the intracellular domain of IL-10R1 are
phosphorylated by cross-phosphorylation and Jak1 and Tyk2 become activated (Kotenko et al.,
1996). Stat3 interacts with these phosphorylated tyrosines to phosphorylate other Stat proteins
that translocate to the nucleus to activate transcription of Stat3-responsive genes (Finbloom and
Winestock, 1995). IL-10 signaling blocks pro-inflammatory cytokine production, chemokine
secretion, and inhibits antigen presentation by macrophages and microglia (Ooboshi et al.,
2005). Furthermore, IL-10 can counteract the detrimental effects of TNF-α by inhibiting
activation of signaling pathways induced by TNF-α (Liesz et al., 2009). IL-10’s beneficial antiinflammatory effects are an attractive target for potential clinical applications in stroke.

Experimental Stroke Studies
Administration of IL-10 into the lateral ventricle 30 minutes and 3 hours after stroke in the
pMCAO electrocoagulation rat model significantly decreases infarct size (Spera et al., 1998). In
the same model, infarct size is significantly decreased when IL-10 is administered 30 minutes
post stroke for 3 hours systemically into the tail vein (Spera et al., 1998). Furthermore, injecting
adenoviral vectors encoding IL-10 into the lateral ventricle 60-90 minutes before photochemical
21

occlusion or bilateral carotid occlusion in rats decreases infarct size and infiltrating leukocytes
(Ooboshi et al., 2005). In a mouse transgenic model in which astrocytes, microglia, and
endothelial brain cells overexpress IL-10, smaller infarcts are observed, and IL-10 deficient mice
show larger infarcts after pMCAO (Grilli et al., 2000; de Bilbao et al., 2009). Another study
suggesting the beneficial role of IL-10 in stroke, found a subset of regulatory B-cells that secrets
IL-10 can decrease infarct size and improve neurological score (Fillatreau et al., 2002; Mann et
al., 2007; Ren et al., 2011). Collectively, all experimental stroke studies suggest that IL-10 is
neuroprotective through suppression of the inflammatory response after ischemia.

Time Course in Experimental Stroke Studies
IL-10 mRNA expression is increased in the ipsilateral cortex of the pMCAO mouse model at 6
hours and peaks at 7 days, and IL-10 receptor mRNA is upregulated after pMCAO (Li et al.,
2001; Perez-de Puig et al., 2013). At 1, 4, and 7 days after pMCAO, IL-10 receptor positive
cells are found in the subarachnoid space and on the surface of the infarcted cortex, and IL-10
receptor positive astrocytes are found in the infarcted tissue at day 4 (Perez-de Puig et al., 2013).
Furthermore in the rat ischemia model, IL-10 is decreased 12 hours after stroke but increases
six-fold two days post-stroke (Li et al., 2001). Few studies have examined the temporal profile
of IL-10 in experimental stroke models, and these studies measured IL-10 mRNA expression in
the brain not in the periphery.

Time Course in Human Studies
More studies have assessed the temporal profile of IL-10 in human subjects. Stroke patients
show lower levels of IL-10 in plasma within 12 hours after stroke compared to controls, and 24
hours after tPA treatment IL-10 levels are increased (Perini et al., 2001; Mazzotta et al., 2004).
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Furthermore, levels of IL-10 are decreased within 24 hours of stroke and levels increase over 72
hours post-stroke (Nayak et al., 2012). Studies report a huge variability in the levels of IL-10,
which is most likely due to the time the sample was taken and stroke severity. Furthermore, the
heterogeneity of co-morbidities among stroke patients could play a role in the variability in
levels of IL-10 and other cytokines after stroke.

1.6. Effects of Cytokines on Stroke Outcome
The inflammatory response to ischemia plays an essential role in the pathophysiology of stroke,
and using inflammatory markers such as the cytokines described above can be useful to predict
outcome after stroke. Increased mortality and functional disability occurs in stroke patients who
show neurological symptoms that progress acutely after stroke onset. The ischemic penumbra is
the tissue that surrounds the infarct core and can survive or be transformed into necrotic tissue
and become part of the infarcted tissue due to reduced blood flow and impaired neuronal
function (Astrup et al., 1981). The transformation of the penumbra to infarcted tissue results in
worsening of neurological symptoms (del Zoppo et al., 2011). Increased levels of IL-6 in both
CSF and serum have been associated with worsening of neurological symptoms, increased
infarct size and poor functional outcome (Tarkowski et al., 1997; Vila et al., 2000a; Beridze et
al., 2011). It is surprising that IL-6 is associated with poor functional outcome in humans since
in experimental stroke studies IL-6 was found to be neuroprotective. However, Ormstad et al.
(2011b) found no correlation between IL-6 and infarct size, and Sotgiu et al. (2006) found an
inverse correlation of IL-6 with infarct size and poor outcome. IL-6 can cause the release of
prostaglandin E2 in the brain, and prostaglandin E2 acts on the hypothalamus resulting in an
increase in body temperature. Numerous human and experimental stroke studies have shown
that fever is correlated with increased infarct size and poor outcome; thus, the early increase in
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IL-6 and prolonged elevation of IL-6 in the CSF and blood most likely correlates with increased
risk of elevated temperature that increases inflammation and tissue damage after stroke.
Moreover, there are conflicting findings when using TNF-α as an inflammatory mediator for
predicting outcome and infarct size. Increased levels of TNF-α in the serum and CSF of stroke
patients is correlated with worsening of neurological symptoms, increased infarct size and poor
outcome at 3 months in studies including severe strokes and patients with white matter damage
(Tarkowski et al., 1995; Zaremba and Losy, 2001; Castellanos et al., 2002; Montaner et al.,
2003; Mazzotta et al., 2004). However, in other studies TNF-α was not correlated with outcome
or infarct size (Vila et al., 2000a; Intiso et al., 2003). Although IL-1β was neurotoxic in all
experimental ischemic animal studies, IL-1β was only found to be correlated with poor outcome
in the plasma of patients in one study which is most likely due to the localized role of IL-1β and
low levels of IL-1β in the blood or CSF (Mazzotta et al., 2004). The anti-inflammatory effects
of IL-10 play an important role in preventing neuronal death; thus, it is not surprising that low
levels of IL-10 early after stroke onset is correlated with poor outcome and increased infarct size
(Mazzotta et al., 2004). However, a trend toward increased levels of IL-10 days after stroke and
even at admission correlate with poor outcome and an increased risk for infection (Chamorro et
al., 2006). Increased IL-10 down regulates TNF-α and inhibits IFN-γ production which can be
beneficial in the earlier phases of infarct progression after stroke; however, the increase in IL-10
can induce peripheral immunosuppression resulting in post-stroke infection and infections are
the leading cause of death in stroke patients (Zhang et al., 2010).

The variability of the data on peripheral cytokines in human stroke is most likely due to the
heterogeneity of stroke in humans. Stroke severity, stroke location, age, co-morbidities, and
systemic inflammation prior to stroke may be key factors contributing to the levels of peripheral
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cytokines seen post-stroke. Furthermore, proper control subjects are important for interpreting
cytokine data. In human stroke studies assessing IL-10, TNF-α, IL-1β, IL-6, and other
inflammatory mediators, the majority of the studies had age-matched controls but some studies
had healthy controls subjects while other studies had controls with co-morbidities such as
hypertension or diabetes. In addition, other studies compared cytokine levels based on stroke
severity. Thus, it is important to control for co-morbidities and risk factors to determine which
and when cytokines are increased due to stroke. Consequently, the use of only one
inflammatory mediator to predict outcome or infarct size is not clinically useful due to the
heterogeneity of the peripheral cytokine response. Therefore, further understanding of when
these cytokines are increased and how they interact with each other can help elucidate how these
cytokines can be used clinically as biomarkers to help predict outcome.

I assessed the effects of these 4 cytokines on neuronal mitochondrial function with the
hypothesis that pro-inflammatory cytokines (TNF-α and IL-1β) would decrease mitochondrial
function resulting in neurotoxicity and anti-inflammatory cytokines (IL-6 and IL-10) would
increase mitochondrial function resulting in neuroprotection. I found that exposure to 1000
ng/ml IL-1β for 12 hours significantly decreased neuronal ATP production and maximal
respiration (Figure 1.1) without causing cell death (data not shown).
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Figure 1.1: ATP production and Maximal respiration after 12 hour exposure to IL-1β. * p < 0.05

IL-6 (Figure 1.2) and IL-10 (Figure 1.3) both increased neuronal mitochondrial function after 6
hours of exposure; however, TNF-α had the most profound dose-dependent effect on neuronal
mitochondrial function; thus, we decided to further investigate the mechanism by which TNF-α
affected mitochondrial function.
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Figure 1.2: ATP production and Maximal respiration after 6 hour exposure to IL-6. * p < 0.05;
** p < 0.01
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Figure 1.3: ATP production and maximal respiration after 6 hour exposure to IL-10.

1.7. Gaps in Knowledge
Since cytokines play an essential role in stroke and have potential clinical utility, it is critical to
understand how experimental and human studies contribute to our knowledge on how to
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effectively use cytokines clinically and how experimental and human studies can be improved to
increase the likelihood of clinically translatable results. An important confounding factor in
understanding the role of peripheral cytokines in human stroke is that experimental stroke
studies observe the cytokine response to stroke in the brain not in the periphery. Furthermore, in
experimental stroke studies both permanent and transient MCAO models are invasive and could
contribute to the cytokine response especially in stroke models that involves craniectomy.
Transient MCAO mimics occlusion and reperfusion while pMCAO mimics just occlusion.
Although reperfusion can attenuate infarction, it allows for increased infiltration of leukocytes
into the brain, and the contribution of cytokines from peripheral leukocytes in affecting the
progression of infarction and the difference in kinetics of leukocytes in the two ischemia models
is not well studied. Thus, further understanding of how reperfusion can affect cytokine levels
and their impact on outcome will be beneficial clinically in patients that receive tPA. Although
outlined above is the signaling mechanisms for TNF-α, few studies have assessed mechanisms
of TNF-α or any other cytokines in stroke, and there is a substantial lack in understanding of
how cytokines balance their neuroprotective and neurotoxic action after stroke. Understanding
this balance is crucial for defining a therapeutic time window for using cytokines as biomarkers
or therapeutic targets.

Understanding the effects of different experimental stroke models on cytokine expression is
important, but equally important is understanding how location of stroke, age, co-morbid
diseases and environmental factors affect cytokine expression in human stroke studies. Thus,
using clinically relevant stroke models such as aged animals, animals with hypertension,
diabetes, etc., and producing strokes in different locations will provide essential information on
cytokine expression that can be more easily translated from the bench to the bedside.
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Additionally, few human stroke studies assess the peripheral cytokine response before 4 hours
after stroke which is a critical time in infarct progression, and early inflammatory events have
been show to play a role in recovery from stroke. Thus, understanding these early cytokines
responses and their effects early post-stroke is critical in using cytokines as biomarkers for
prognosis and therapeutic targets. Designing clinical stroke studies to have power to do analysis
on cytokine expression controlling for time, location, and co-morbidities and designing preclinical stroke studies to assess cytokine expression in peripheral blood as well as brain will be
critical for the use of cytokines as prognostic biomarkers for stroke.
While prognostic biomarkers are important clinically, it is equally as important to find new
therapeutic targets for stroke. Currently there is only one FDA approved drug for stroke, tPA,
that less than 5% percent of patients receive. Thus, understanding the mechanism by which
cytokines such as TNF-α exacerbate stroke damage and the expression of these cytokines pre
and post-stroke is critical for the advancement of stroke research.

1.8. Summary
It is clear that cytokines play an important role in the pathophysiology and etiology of stroke,
and the loss in balance between pro-inflammatory and anti-inflammatory cytokines affects
infarct size and functional outcome. Thus, focusing on one cytokine only as a potential
biomarker or a therapeutic target likely will not be advantageous in stroke. Future work needs to
elucidate the temporal profile of cytokines in the periphery in human and experimental stroke
studies to determine which cells contribute to the elevation of cytokines in the brain and blood
and to understand how they work in concert to provide neuroprotection or increase
neurotoxicity. The crosstalk between the immune system and the brain is still not well
understood. Using cytokines as biomarkers or therapeutic targets may be beneficial to
29

understand the post-ischemic immune response and its effects on outcome clinically and to
modulate the post-ischemic immune response to limit tissue damage. However, modulation of
the immune response can also be detrimental after stroke; thus, it is imperative that further
clinical and experimental studies be pursued to better understand the complex interaction
between the immune system and the brain after stroke. Moreover, understanding how having a
stroke during an active infection or a pro-inflammatory state contributes to the long-term deficits
post-stroke is essential for future treatment of stroke. Numerous risk factors such as diabetes,
hypertension, and atherosclerosis have been recognized to increase susceptibility to stroke;
however, the epidemiology of ischemic stroke is not sufficiently explained by the prevalence of
these cerebrovascular risk factors (Grau et al., 1995b). In at least a third of ischemic stroke
cases, the patients lack traditional risk factors and have no apparent cause. The presence of
systemic infection could be an important mediating risk factor. Indeed, thirty to forty percent of
strokes occur during or acutely after an infection (Grau et al., 1995b) suggest an association
between systemic infection and stroke. Recent studies have indicated that both Helicobacter
pylori (H. pylori) (Wang et al., 2012) and human cytomegalovirus (HCMV) (Huang et al., 2012)
infections are associated with increased risk for ischemic stroke. Moreover, having a
respiratory tract infection increases one’s risk for an atherothrombotic ischemic event for up to 3
months (Zurru et al., 2009) and chronic bronchitis increases risk for stroke and transient
ischemic attacks (TIA) (Grau et al., 2009). Lastly, Grabska et al. (2011) conducted a
retrospective chart review of 2066 ischemic stroke patients to assess the effect of pre-stroke and
post-stroke infection on ischemic stroke severity and found that pre-stroke infection increased
poor outcomes within the first 30 days but did not have effects at 90 days on modified Rankin
scores. Thus whether it is traditional stroke risk factors or infection that increases susceptibility
to stroke, a key feature is an increased pro-inflammatory profile. McColl et al. (2007) found that
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the combination of a minor bacterial infection mimic, lipopolysaccharide (LPS) prior to a minor
stroke exacerbates infarct volume in a mouse model. Thus, experimental and epidemiological
data strongly suggest that infection and/or inflammation play a role in stroke occurrence and
severity. However, to date, long-term outcomes of stroke during an active infection has not been
studied.

Thus, my dissertation will use post-stroke relevant concentrations of TNF-α and clinically
relevant exposure times to understand 1) if TNF-α affects neuronal mitochondrial function and
2) if TNF-α affects neuronal mitochondrial function, the mechanism by which it occurs.
Additionally, my dissertation will focus on 3) if a bacterial infection mimic, lipopolysaccharide
(LPS), prior to stroke affects stroke outcome.
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Rapid mitochondrial dysfunction mediates
TNF-alpha induced neurotoxicity
Danielle N. Doll, Stephanie L. Rellick, Taura L. Barr,
Xuefang Ren, and James W. Simpkins
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2.1. Abstract
Tumor necrosis factor alpha (TNF-α) is known to exacerbate ischemic brain injury; however, the
mechanism is unknown. Previous studies have evaluated the effects of TNF-α on neurons with
long exposures to high doses of TNF-α, which is not pathophysiologically relevant. We
characterized the rapid effects of TNF-α on basal respiration, ATP production, and maximal
respiration using pathophysiologically relevant, post-stroke concentrations of TNF-α. We
observed a reduction in mitochondrial function as early as 1.5 hours after exposure to low doses
of TNF-α, followed by a decrease in cell viability in HT-22 cells and primary neurons.
Subsequently, we used the HT-22 cell line to determine the mechanism by which TNF-α causes
a rapid and profound reduction in mitochondrial function. Pre-treating with TNF-R1 antibody,
but not TNF-R2 antibody, ameliorated the neurotoxic effects of TNF-α indicating TNF-α exerts
its neurotoxic effects through TNF-R1. We observed an increase in caspase 8 activity and a
decrease in mitochondrial membrane potential after exposure to TNF-α which resulted in a
release of cytochrome c from the mitochondrial into the cytosol. These novel findings indicate
for the first time that an acute exposure to pathophysiologically relevant concentrations of TNFα has neurotoxic effects mediated by a rapid impairment of mitochondrial function.
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2.2. Introduction
Inflammatory mechanisms play a crucial role in the pathophysiologic processes after the onset of
ischemic stroke (Vila et al., 2000a). Ischemic brain injury is complex, and intracellular
signaling that regulates innate and adaptive immunity, inflammation, cell death, angiogenesis,
and repair processes plays an important role in the initiation, progression, and resolution of
ischemia. Initiation of these critical intracellular regulators occurs through rapid cytokine
signaling after ischemia, highlighting cytokines as key regulators of stroke damage (Hallenbeck,
2002). TNF-α is one of many pro-inflammatory cytokines associated with worsened clinical
outcomes after stroke and exacerbations of infarct size in pre-clinical models (Nawashiro et al.,
1997c; Ormstad et al., 2011a). However, our understanding of the pro-inflammatory effects of
TNF-α is based primarily on studies of its peripheral actions.

TNF-α mRNA increases within 1 hour in the ischemic injury core, and the expression of its
immunoreactive protein increases within 2-6 hours after the onset of ischemia in pre-clinical
models (Botchkina et al., 1997). TNF-α is increased in the serum of stroke patients between 6
and 12 hours after symptom onset (Liu et al., 1994; Sotgiu et al., 2006). TNF-α signaling
occurs through the TNF-α receptor (TNF-R), where ligand binding recruits adaptor proteins to a
core signaling complex allowing for differences in signal transduction depending upon the
stimulatory pattern (Wallach et al., 2002).

The response to TNF-α is cell-type dependent. In bovine and rat oligodendrocytes, TNF-α
induces apoptosis, while in astrocytes, TNF-α enhances major histocompatibility complex
(MHC) class II and intracellular adhesion molecule 1 (ICAM-1) expression (Chao et al., 1995).
In primary septo-hippocampal cultures, exposure to 30 ng/ml of TNF-α caused significant
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cytotoxicity but only with the addition of Actinomycin-D (Zhao et al., 2001). When rat primary
cortical neurons are exposed to 10 ng/ml of TNF-α for 24 hours, neurite retraction or formation
of apoptotic bodies were not observed (Reimann-Philipp et al., 2001). However, in PC12 cells,
TNF-α was cytotoxic (Reimann-Philipp et al., 2001). While these studies show neurotoxic
effects of TNF-α, cultured embryonic rat hippocampal, septal, and cortical neurons are protected
from glucose deprivation-induced injury and excitatory amino acid toxicity by exposure to TNFα (Cheng et al., 1994). Furthermore, TNF-α can induce the expression of anti-apoptotic proteins
B-cell lymphoma 2 (Bcl-2) and B-cell lymphoma-extra large (Bcl-xl) in hippocampal neurons
(Tamatani et al., 1999). These few studies used high concentrations and long periods of
exposure to TNF-α. Also, there is a single study, of adipocytes that used high concentrations and
4 day exposures to assess mitochondrial function (Chen et al., 2010).

In the present study, we tested the hypothesis that acute exposure to TNF-α concentrations seen
in serum of stroke patients (Lambertsen et al., 2012; Nayak et al., 2012) causes neuronal cell
death through rapid mitochondrial dysfunction. As such, we characterized the effect of acute
exposure to low doses of TNF-α in a mouse hippocampal neuronal cell line (HT-22) and mouse
primary cortical neurons. A rapid and profound mitochondrial dysfunction was observed after
as little as 1.5 hours of exposure to TNF-α which preceded cell death. These findings suggest
that the damaging effect of TNF-α may be due to the impairment of neuronal mitochondrial
function.
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2.3. Materials and Methods
Cell Culture
An immortalized mouse hippocampal cell line, HT-22, was cultured in Hyclone DMEM/high
glucose (Fisher Scientific, Waltham, MA) with 10% fetal bovine serum (FBS) (Atlanta
Biologicals, Flowery Branch, GA) and 1% penicillin/streptomycin (Fisher Scientific). The HT22 mouse hippocampal neuronal cell line was provided by The Salk Institute for Biological
Research (La Jolla, CA), and cell passages 15 – 23 were used. When HT-22 cells were at least
80% confluent, the cells were trypsinized and spun down at 1500 RPM for 3 minutes. The cells
were counted with Nexcelom Bioscience Cellometer AutoT4 (Lawrence, MA). Primary mouse
cortical neurons were purchased from Life Technologies (Carlsbad, CA) and cultured in
Neurobasal® Medium supplemented with GlutaMAXTM – I and B-27® supplement (Life
Technologies).

TNF-α Treatment
Recombinant Mouse TNF-α was purchased from R&D Systems (Minneapolis, MN) and
reconstituted at 50 µg/ml in phosphate buffered saline (PBS) containing 0.1% bovine serum
albumin (BSA). Dilutions were made in Hyclone DMEM/high glucose with 10% FBS and 1%
penicillin/streptomycin to obtain concentrations of 1, 10, 100, and 1000 pg/ml. The media was
removed from each well by gentle aspiration. After removing the media, 100 ul of Hyclone
DMEM/high glucose or the various concentrations of TNF-α were added for either 1.5, 3, 6, or
12 hours. These time points were chosen based upon the post-stroke increase in TNF-α in serum
patients and in the brains of animal models (Liu et al., 1994; Botchkina et al., 1997; Zaremba
and Losy, 2001; Intiso et al., 2003). For primary mouse cortical neurons, TNF-α at
concentrations of 0, 100 and 1000 pg/ml were added for 1.5, 3, 6 and 24 hours.
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Mitochondrial Function Assessment
15,000 HT-22 cells or 16,000 primary mouse cortical neurons were seeded in a XFe96 cell
culture microplate. HT-22 cells were treated with 1- 1000 pg/ml of TNF-α (6 replicates per
treatment condition) 24 hours after seeding. Primary mouse cortical neurons were treated with
100 or 1000 pg/ml of TNF-α 3 days after seeding. After treating with TNF-α, mitochondrial
function was assessed with the XFe 96 Analyzer (Seahorse Bioscience, North Billerica, MA)
using a Mito Stress test kit at 1.5, 3, 6, and 12 hours (HT-22 cells) or 1.5, 3, 6, and 24 hours
(primary neurons). Non-mitochondria derived oxygen consumption rate (OCR) was measured
using the first measurement after addition of rotenone and antimycin a. To calculate basal
respiration, the measurement prior to oligomycin addition was subtracted from nonmitochondria derived OCR. Proton leak was measured using the third measurement after
oligomycin injection subtracted from non-mitochondrial derived OCR. ATP production was
measured from subtracting proton leak from basal respiration. Maximal respiration was
calculated using the first measurement after FCCP injection subtracted from non-mitochondria
derived OCR.

Cell Viability
Cell viability was assessed using Calcein AM (Life Technologies), and reconstituted at 2mM in
DMSO. 15,000 HT-22 cells or 16,000 primary mouse cortical neurons were seeded in a blackwalled clear bottom 96 well plate. HT-22 cells were exposed to 1 – 1000 pg/ml of TNF-α and
the primary mouse cortical neurons were treated with 100 or 1000 pg/ml of TNF-α. After
exposure to TNF-α for 1.5, 3, 6, and 12 hours (HT-22 cells) or 1.5, 3, 6, and 24 hours (primary
neurons), the plate was washed three times with PBS 1X. 100 ul of 1uM Calcein AM was added
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to the wells. The plate was incubated at room temperature in the dark for 30 minutes. The plate
was read using a BioTek Synergy H1 Hybrid reader (Winooski, VT).

Flow Cytometry
HT-22 cells were grown to 90% confluence, a single cell suspension was made using cell
dissociation buffer, and the cells were fixed in 10% formaldehyde for 30 minutes and
subsequently permeabilized in 70% ethanol for 30 minutes on ice. To reduce non-specific
antibody binding, HT-22 cells were blocked in 3% BSA in PBS for 15 minutes and subsequently
incubated with 1ug PE anti-mouse CD120a (TNF R Type I/p55) or PE anti-mouse CD120b
(TNF R Type II/p75) from Biolegend (San Diego, CA). Data were acquired by counting 10,000
events and analyzed using FACSCalibur (BD Biosciences, San Jose, CA) to determine the
presence or absence of TNF-R1 and/or TNF-R2.

TNF-R1 or TNF-R2 antibody Treatment
HT-22 cells were pre-treated for 1 hour with 4, 6, or 8 ug/ml of LEAFLM Purified anti-mouse
CD120a (TNF R Type I/p55), 4, 6, or 8 ug/ml of LEAFLM Purified anti-mouse CD120b (TNF R
Type II/p75), or 8 ug/ml of LEAFLM Purified Armenian Hamster IgG Isotype Ctrl from
Biolegend. Media was removed and cells were then treated with 100 pg/ml of TNF-α for 1.5
hours or 3 hours. Cell viability was assessed with Calcein AM at both 1.5 and 3 hours, and
mitochondrial basal respiration was assessed with the XFe 96 Analyzer from Seahorse
Bioscience at 1.5 hours.
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Caspase 8 and Caspase 3/7 Activity
Caspase 8 and Caspase3/7 activity was assessed with the Caspase-Glo TM 8 and Caspase-Glo TM
3/7 assay kits (Promega, Madison, WI) after treating HT-22 cells with 1, 10, 100, 1000 pg/ml of
TNF-α for 1.5 hours.

TMRE Mitochondrial Membrane Potential Assay
Mitochondrial membrane potential was assayed using a TMRE mitochondrial membrane
potential assay (Abcam,Cambridge, MA) by addition of 300 nM TMRE and 20 μM FCCP after
treating HT-22 cells with 1, 10, 100, 1000 pg/ml of TNF-α for 1.5 hours.

Cytochrome c release from mitochondria to cytosol
After exposure to 100 or 1000 pg/ml of TNF-α for 3, 6, 12, and 24 hours, HT-22 cells were
fractioned into cytosolic and mitochondrial fractions using the Mitochondrial/Cytosol
Fractionation Kit (Biovision, Milpitas, CA). The protein concentration of each fraction was
determined using the Pierce 660nm protein assay (Thermo Scientific, Waltham, MA).
Cytochrome c levels in the cytosolic and mitochondrial fractions were determined using a
rat/mouse cytochrome c Quantikine ELISA (R&D Systems, Minneapolis, MN). Percentage
release of cytochrome c was calculated using the following equation: total cytosolic cytochrome
c/ (cytosolic + mitochondrial cytochrome c) (Tanaka et al., 2004).

Statistical Analysis
One-way ANOVA and post hoc analyses (Dunnett or Trend for linear analysis) were used to
analyze differences among groups using GraphPad Prism 5 software. Statistical significance was
determined at a p < 0.05.
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2.4. Results
TNF-α caused a decrease in mitochondrial function at 1.5, 3, 6, and 12 hours in HT-22 cells
Figure 2.1 (A, C, E, G) and Supplemental Figure 1 show the dose-dependent decrease in basal
respiration, ATP production, and maximal respiration at 1.5, 3, 6, and 12 hours of TNF-α
exposure. At 1.5 hours, basal respiration, ATP production, and maximal respiration decreased
by approximately 30%, and 40% at 100 and 1000 pg/ml TNF-α, respectively (Figure 2.1A and
Supplemental Figure 2.1A). At 3 and 12 hours, but not 6 hours, the magnitude of the dosedependent reduction in basal respiration, ATP production, and maximal respiration induced by
TNF-α was increased (Figure 2.1 C, E, G and Supplemental Figure B – D).

TNF-α caused a delayed decrease in cell viability in HT-22 cells
Based on our observation of decreased mitochondrial function as early as 1.5 hours of TNF-α
exposure, we determined if the decrease in mitochondrial function preceded cell death. We did
not observe a significant decrease in cell viability after 1.5 hours of exposure to TNF-α (Figure
2.1 B). However, cell viability began to decrease after 3 hours by approximately 30% at doses
of 100 and 1000 pg/ml of TNF-α (Figure 2.1 D). Additionally, cell viability decreased
significantly at 6 and 12 hours (Figure 2.1 F and H). At 6 hours, 100 and 1000 pg/ml of TNF-α
caused a decrease in cell viability of approximately 37%. At 12 hours, 10, 100, and 1000 pg/ml
caused a decrease in cell viability of approximately 50%.

TNF-α caused a rapid decrease in mitochondrial function and a delayed decrease in cell
viability in mouse primary cortical neurons
To confirm the rapid and profound effects of low doses of TNF-α on mitochondrial function was
not specific to a transformed cell line, we exposed mouse primary cortical neurons to low doses
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of TNF-α for 1.5, 3, 6, and 24 hours. After exposure to 100 pg/ml and 1000 pg/ml of TNF-α for
1.5 hours, basal respiration was decreased by 48% and 61%, respectively without causing cell
death (Figure 2.2 A and B). Acute exposure to low doses of TNF-α did not decrease cell
viability until 24 hours after exposure to 1000 pg/ml of TNF-α (Figure 2.2 H). Since TNF-α
rapidly decreases mitochondrial function prior to cell death in both HT-22 cells and mouse
primary cortical neurons, we used the HT-22 cell line to determine the mechanism by which
TNF-α rapidly affects mitochondrial function.

HT-22 cells express TNF-R1 and TNF-R2
It is known that TNF-α mediates its effects through TNF-R1 and TNF-R2. There is expression
of TNF-R1 on all cell types, while expression of TNF-R2 is primarily on hemopoietic and
endothelial cells (Maddahi et al., 2011). To determine the expression pattern of TNF-α receptors
on HT-22 cells, flow cytometry analysis of HT-22 cells with antibodies specific for TNF-R1
and TNF-R2 was performed. HT-22 cells expressed both TNF-R1 (24.56%) and TNF-R2
(87.17%) under normal culture conditions (Supplemental Figure 2.2).

TNF-α exerts its neurotoxic effects through TNF-R1
Pre-treating HT-22 cells with 4, 6, or 8 ug/ml of TNF-R1 antibody for 1 hour ameliorated the
TNF-α induced decrease in mitochondrial basal respiration (Figure 2.3 A), ATP production, and
maximal respiration (data not shown) at 1.5 hours. As observed in Figure 2.1 B, TNF-α did not
kill HT-22 cells at 1.5 hours (Figure 2.3 B and E). The decrease in cell viability caused by 100
pg/ml of TNF-α at 3 hours was ameliorated when TNF-R1 was blocked (Figure 2.3 C).
However, when HT-22 cells were pre-treated with 4, 6, or 8 ug/ml of TNF-R2 antibody, the
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neurotoxic effects of TNF-α on mitochondrial basal respiration at 1.5 hours (Figure 2.3 D) or
cell viability at 3 hours (Figure 2.3 F) was not affected.

TNF-α caused an increase in caspase 8 activity but not caspase 3/7 activity in HT-22 cells
After exposure to 1, 10, 100, 1000 pg/ml of TNF-α for 1.5 hours, caspase 8 and caspase 3/7
activity was assessed with caspase 8 and caspase 3/7 luciferase assays. TNF-α caused a dosedependent increase in caspase 8 activity (Figure 2.4 A); however, caspase 3/7 activity was not
affected by TNF-α exposure at this early time (Supplemental Figure 2.3). At the highest TNF-α
concentration of 1000 pg/ml, caspase 8 activity was increased by 46%.

TNF-α caused a decrease in mitochondrial membrane potential in HT-22 cells
Mitochondrial membrane potential dissipation results from the activation of caspases; thus, the
increase in caspase 8 activity after 1.5 hours of exposure to TNF-α led us to hypothesize that
TNF-α causes mitochondrial membrane potential to decrease as a result of the activation of
caspase 8. TNF-α exposure for 1.5 hours resulted in a significant dose-dependent decrease in
mitochondrial membrane potential (Figure 2.4 B), and there was a significant correlation
between the increase in caspase 8 activity and decrease in mitochondrial membrane potential
(Figure 2.4 C).

TNF-α induced cytochrome c release from mitochondria in HT-22 cells
After exposure to 100 and 1000 pg/ml of TNF-α for 3, 6, 12, and 24 hours, there was a dosedependent increase in cytochrome c release from mitochondria (Figure 2.5). Exposure to TNF-α
for 3, 12, and 24 hours with 100 and 1000 pg/ml TNF-α resulted in a significant increase in
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cytochrome c release, and after exposure for 6 hours only 1000 pg/ml of TNF-α resulted in a
significant increase in cytochrome c release (p < 0.05).

2.5. Discussion
The present study shows, for the first time, that TNF-α rapidly and profoundly reduces neuronal
cell mitochondrial function. It is widely accepted that mitochondria play a role in neuroinflammation and neurodegenerative CNS disorders such as multiple sclerosis, Alzheimer’s
disease, and Parkinson’s disease (Di Filippo et al., 2010). With an insult like ischemic stroke,
activation of microglia occurs that leads to the release of TNF-α along with other proinflammatory cytokines (Davalos et al., 2005). Pro-inflammatory cytokines can activate
mitochondria-induced apoptosis leading to cell death (Huang et al., 2005). Our findings suggest
that TNF-α exposure caused neuronal mitochondrial dysfunction as expressed by decreased
mitochondrial respiration as early as 1.5 hours of exposure.

Neurons have a high ATP demand (Zhu et al., 2012), and a temporary reduction in ATP
production results in a profound decrease in neuronal viability (Simpkins et al., 2010). Fiskum
et al. (1999) hypothesized that neuronal death that occurs at the core of an infarct after ischemia
results from the decrease in mitochondrial and glycolytic ATP production. TNF-α is known to
exacerbate infarct size in pre-clinical models of stroke, and this may be due to the profound and
rapid decrease in ATP production, caused by TNF-α release in the evolving ischemic core.
Although TNF-R2 is primarily expressed on immune cells, and the expression of TNF-R1 is
constitutive on all cell types, HT-22 cells express both receptors (Maddahi et al., 2011). TNFR2 plays a major role in the lymphoid system and requires membrane bound TNF-α for full
activation; thus, we hypothesized that TNF-α affects mitochondrial function through TNF-R1
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because soluble TNF-α signaling is primarily through TNF-R1 (Wajant et al., 2003; Maddahi et
al., 2011). Furthermore, there is no correlation between the number of receptors present on a
cell and the magnitude of the TNF-induced response (Beyaert and Fiers, 1994). Blocking TNFR1 ameliorated the neurotoxic effects of TNF-α on mitochondrial respiration and cell viability,
confirming TNF-α exerts neurotoxic effects through TNF-R1 not TNF-R2. To further
understand the neurotoxic mechanisms of TNF-α, we assessed caspase 8 and caspase 3/7 activity
because TNF-α can signal through TNF-R1 and activate caspase 8 or caspase 3/7 (Baud and
Karin, 2001; McCoy and Tansey, 2008). The activation of caspase 8 causes mitochondrialinduced apoptosis through the cleavage of Bcl-2-associated X protein (BAX) and BH3
interacting-domain death agonist (BID) (Aggarwal, 2003; McCoy and Tansey, 2008). Caspase 8
activity was increased in a dose-dependent manner after exposure to TNF-α for 1.5 hours;
however, caspase 3/7 activity was not affected at this early time. The increase in caspase 8
activity led us to hypothesize that mitochondrial membrane potential should decrease if caspase
8 is initiating mitochondrial-induced apoptosis (Green and Kroemer, 2004). The TMRE
mitochondrial membrane potential assay showed a significant dose-dependent decrease in
mitochondrial membrane potential after 1.5 hour of TNF-α exposure. Furthermore, with a
collapse of mitochondrial membrane potential there should be an increase in cytochrome c release
from the mitochondria, due to the cleavage of BAX and BID (Baud and Karin, 2001; Aggarwal,
2003; McCoy and Tansey, 2008). After exposure to 100 pg/ml of TNF-α for 3 and 24 hours,
there was an 11% and 68% increase in cytochrome c release, respectively, from mitochondria.
Our observation of a 19.7% decrease in mitochondrial membrane potential and the 30% decrease
in ATP production at 1.5 hours of treatment with 100 pg/ml TNF-α indicates that sufficient
cytochrome c is released to induce apoptosis (Sas et al., 2007). Once cytochrome c is released,
cytochrome c interacts with apoptotic protease-activating factor-1 (Apaf-1), procaspase-9, and
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dATP forming an apoptosome (Sas et al., 2007). The formation of the apoptosome allows for
the activation of caspase-9, which activates procaspase-3, and results in the induction of
apoptosis (Sas et al., 2007).

HT-22 cells and primary mouse cortical neurons both showed a rapid mitochondrial impairment
and subsequent cell death in response to low concentrations of TNF-α. However, there was a
notable difference between the two cell types in the timing of the TNF-α induced cell death.
Whereas HT-22 cells died within 3 hours of exposure, primary neurons showed cell loss only at
24 hours. The reason for this delayed response of primary neurons is not clear, but is consistent
with the comparative resistance of primary neurons to TNF-α in other studies (Reimann-Philipp
et al., 2001; Zhao et al., 2001). We suspect, but do not have evidence to support, that primary
neurons may have inherent defense mechanisms that resist the neurotoxic effects of a single
cytokine, like TNF-α (Tamatani et al., 1999).

Numerous studies reported an association between increased levels of TNF-α mRNA and protein
and an exacerbation of ischemic injury (Di Filippo et al., 2010). Administration of TNF-αblocking antibodies or soluble TNF-R1 prior to inducing stroke reduces infarct volume
(Murakami et al., 2005; Di Filippo et al., 2010). Our findings may provide the mechanism of
TNF-α exacerbation of stroke damage and shows that TNF-α elicits neurotoxic effects by
inducing a rapid mitochondrial dysfunction mediated through TNF-R1 signaling subsequently
activating caspase 8 and leading to the release of cytochrome c.
Current clinical treatment of ischemic stroke concentrates on dissolving and/or removing the
clot, without much focus on the secondary damage that occurs as part of the inflammatory
ischemic cascade (Works et al., 2013). Inflammation is known to play a major role in the
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pathophysiology of stroke and progression of damage post-stroke (Vila et al., 2000a; Iadecola
and Anrather, 2011). The identification of a new therapeutic to reduce brain damage due to
inflammation post-stroke would be clinically useful. However, TNF-α has both pro-apoptotic
and anti-apoptotic activities, and both roles are important physiologically (Aggarwal, 2003).
When the expression of TNF-α is profound and prolonged, such as after stroke, it has harmful
effects (Aggarwal, 2003). Thus, understanding the neurotoxic mechanism of TNF-α is
important to further advance its potential as a therapeutic target.

As with all in vitro studies, our studies have some limitations, and we interpreted our results
with caution. First, TNF-α was administered at discrete doses (1-1000 pg/ml) for 1.5 to 24
hours. Post- stroke concentrations change over time and are elevated in patients within 6 hours
of symptom onset and stay elevated for up to 10 days (Zaremba and Losy, 2001; Intiso et al.,
2003). Furthermore, TNF-α mRNA is increased in the ischemic core within 1 hour, and TNF-α
immunoreactive protein is seen within 2-6 hours in the brain after middle cerebral artery
occlusion, (MCAO) in preclinical models (Liu et al., 1994; Botchkina et al., 1997). We
observed mitochondrial impairment with clinically relevant concentrations of TNF-α over a
critical time window post-stroke. An additional limitation is the use of cell culture models such
as a transformed cell line and a primary mouse neuronal culture. Both cell types are models for
neurons, but do not have astrocytes, microglia, or endothelial cells; thus, the results should be
taken with caution. In view of the similarity between the two models, we believe we have
modeled the effects of TNF-α on nerve cells. Finally, we did not evaluate cleavage of BAX and
BID. We assumed the cleavage occurred because caspase 8 cleaves BAX and BID, resulting in
cytochrome c release. Our results support that exposure to TNF-α at 1.5 hours results in an
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increase in caspase 8 activity, and by 3 hours we observed a significant release of cytochrome c
from the mitochondria into the cytosol.

This study shows, for the first time, a rapid and profound mitochondrial dysfunction in neurons
with acute exposure to low doses of TNF-α. This neurotoxic effect of TNF-α appears to be
mediated by TNF-R1, leading to caspase activation, mitochondrial membrane potential collapse,
and mitochondrial release of cytochrome c. Collectively these data help to elucidate the
neurotoxic mechanisms of TNF-α, and thereby, provides potential targets for cytokine directed
therapy for neuroprotection.
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Figure Legends
Figure 2.1: Effects of TNF-α on basal respiration and cell viability in HT-22 cells. (A) Basal
respiration after exposure to TNF-α for 1.5 hours. (B) Cell viability after exposure to TNF-α for
1.5 hours. (C) Basal respiration after exposure to TNF-α for 3 hours. (D) Cell viability after
exposure to TNF-α for 3 hours. (E) Basal respiration after exposure to TNF-α for 6 hours. (F)
Cell viability after exposure to TNF-α for 6 hours. (G) Basal respiration after exposure to TNFα for 12 hours. (H) Cell viability after exposure to TNF-α for 12 hours. Analysis of variance and
Dunnett post-hoc tests were used to assess significance. * p < 0.05; ** p < 0.01; *** p < 0.001.
Depicted are mean + SEM for n = 6/group.

Figure 2.2: Effects of TNF-α on basal respiration and cell viability in mouse primary cortical
neurons. (A) Basal respiration after exposure to TNF-α for 1.5 hours. (B) Cell viability after
exposure to TNF-α for 1.5 hours. (C) Basal respiration after exposure to TNF-α for 3 hours. (D)
Cell viability after exposure to TNF-α for 3 hours. (E) Basal respiration after exposure to TNF-α
for 6 hours. (F) Cell viability after exposure to TNF-α for 6 hours. (G) Basal respiration after
exposure to TNF-α for 24 hours. (H) Cell viability after exposure to TNF-α for 24 hours.
Analysis of variance and Dunnett post-hoc tests were used to assess significance. * p < 0.05; **
p < 0.01; *** p < 0.001. Depicted are mean + SEM for n = 6/group. When SEM is not depicted,
it is too small for representation.

Figure 2.3: Effects of blocking TNF-R1 or TNF-R2 on TNF-α induced changes in
mitochondrial basal respiration and cell viability. (A) Effects of TNF-R1 antibody on TNF-α
induced changes in mitochondrial basal respiration at 1.5 hours. (B) Effects of TNF-R1
antibody on TNF-α induced changes in cell viability at 1.5 hours. (C) Effects of TNF-R1
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antibody on TNF-α induced changes in cell viability at 3 hours. (D) Effects of TNF-R2 antibody
on TNF-α induced changes in mitochondrial basal respiration at 1.5 hours. (E) Effects of TNFR2 antibody on TNF-α induced changes in cell viability at 1.5 hours. (F) Effects of TNF-R2
antibody on TNF-α induced changes in cell viability at 3 hours. Analysis of variance and
Dunnett post-hoc tests were used to assess significance, * p< 0.05, *** p< 0.001; ## p < 0.01;
### p< 0.001; * compared to Vehicle; # compared to 100 pg/ml TNF-α; Depicted are mean +
SEM for n = 6/group.

Figure 2.4: (A) Effects of 1.5 hours of exposure to TNF-α on caspase 8 activity. Analysis of
variance and Dunnett post-hoc tests were used to assess significance, *** p < 0.001 (B) Effects
of 1.5 hours of treatment with TNF-α on mitochondrial membrane potential. Analysis of
variance with post-test for linear trend found a significant dose-dependent decrease in
mitochondrial membrane potential, R square = 0.3571, p = 0.0163 Pearson’s correlation
between caspase 8 activity and mitochondrial membrane potential. R square = 0.9437, p =
0.086. Depicted are mean + SEM for n = 6/group.

Figure 2.5: Effects of TNF-α on cytochrome c release. (A) Exposure to TNF-α for 3 hours. (B)
Exposure to TNF-α for 6 hours. (C) Exposure to TNF-α for 12 hours. (D) Exposure to TNF-α
for 24 hours. Analysis of variance and Dunnett post-hoc tests were used to assess significance. *
p < 0.05; ** p < 0.01; *** p < 0.001. Depicted are mean + SEM for n = 6/group. When SEM is
not depicted, it is too small for representation.
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Supplemental Figure Legends
Supplemental Figure 2.1: Effects of TNF-α on ATP production and maximal respiration. (A)
Exposure to TNF-α for 1.5 hours. (B) Exposure to TNF-α for 3 hours. (C) Exposure to TNF-α
for 6 hours. (D) Exposure to TNF-α for 12 hours. Analysis of variance and Dunnett post-hoc
tests were used to assess significance. * p < 0.05; ** p < 0.01; *** p < 0.001. Depicted are mean
+ SEM for n = 6/group.

Supplemental Figure 2.2: Flow cytometry analysis of HT-22 cell expression of TNF-R1 and
TNF-R2.

Supplemental Figure 2.3: Effects of 1.5 hours of exposure to TNF-α on caspase 3/7 activity.
Analysis of variance did not show a significant difference among the groups. Depicted are mean
+ SEM for n = 6/group. When SEM is not depicted, it is too small for representation.
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Chapter 3
Mitochondrial Crisis in Cerebrovascular
Endothelial Cells Opens the Blood-Brain
Barrier
Danielle N. Doll, Heng Hu, MD, Jiahong Sun, Sara E.
Lewis, MS, James W. Simpkins, PhD, Xuefang Ren

Doll DN, Hu H, Sun J, Lewis SE, Simpkins JW, Ren X. (2015)
Mitochondrial Crisis in Cerebrovascular Endothelial Cells
Opens the Blood-Brain Barrier. Stroke, 46, 1681 – 1689.
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3.1. Abstract
Background and Purpose--The blood-brain barrier (BBB) is a selectively permeable
cerebrovascular endothelial barrier that maintains homeostasis between the periphery and central
nervous system (CNS). BBB disruption is a consequence of ischemic stroke and BBB
permeability can be altered by infection/inflammation, but the complex cellular and molecular
changes that result in this BBB alteration need to be elucidated to determine mechanisms.
Methods—Infection mimic (LPS) challenge on infarct volume, BBB permeability, infiltrated
neutrophils and functional outcomes following murine transient middle cerebral artery occlusion
(tMCAO) in vivo; mitochondrial evaluation of cerebrovascular endothelial cells (CVECs)
challenged by LPS in vitro; pharmacological inhibition of mitochondria on BBB permeability in
vitro and in vivo; the effects of mitochondrial inhibitor on BBB permeability, infarct volume and
functional outcomes following tMCAO.
Results--We report here that LPS worsens ischemic stroke outcome and increases BBB
permeability following tMCAO in mice.

Further, we elucidate a novel mechanism that

compromised mitochondrial function accounts for increased BBB permeability as evidenced by:
LPS-induced reductions in oxidative phosphorylation and subunit expression of respiratory
chain complexes in CVECs, a compromised BBB permeability induced by pharmacological
inhibition of mitochondrial function in CVECs in vitro and in an in vivo animal model, and
worsened stroke outcomes in tMCAO mice following inhibition of mitochondrial function.
Conclusions--We concluded that mitochondria are key players in BBB permeability. These
novel findings suggest a potential new therapeutic strategy for ischemic stroke by endothelial
cell mitochondrial regulation.
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3.2. Introduction
The blood-brain barrier (BBB) is a highly specialized vascular interface that maintains
homeostasis in brain by separating the blood compartment from the central nervous system
(CNS). Disruption of cerebrovascular endothelial cells not only allows entry of unwanted solutes
into brain, but also disrupts the normal CNS entry route of critical nutrients (Rubin and Staddon,
1999; Gonzalez-Mariscal et al., 2000). Disruption and/or dysfunction of the BBB has been
observed in cerebrovascular diseases and neurodegenerative disorders such as stroke,
Alzheimer’s disease (AD), Parkinson disease (PD), Huntington’s disease and epilepsy (Tajes et
al., 2014).

Stroke is the second leading cause of death and the leading cause of disability worldwide (Feigin
et al., 2014). It is estimated that 30-40% of all strokes occur during or recently after an acute
infection (Grau et al., 1995b). Acute infections initiate rapid inflammation, and post-stroke
infections worsen outcomes in patients (Grau et al., 1995a) and in animal models (McColl et al.,
2007). However, the mechanisms of this exacerbation by infection on acute stroke outcome are
not completely understood.

Ischemia and reperfusion events result in complex cellular and molecular changes that further
need to be elucidated. Thus far, studies have provided evidence that the release of oxidants,
proteolytic enzymes and inflammatory cytokines alter BBB permeability. The BBB excludes
the majority of bacteria; however, similar to ischemia and reperfusion, inflammation induced by
bacteria alters BBB permeability. Lipopolysaccharide (LPS) has been shown to disrupt the BBB
in vivo and in vitro, however, how LPS exerts its effects on the BBB is under debate (Banks and
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Erickson, 2010). Previous studies found that an LPS challenge results in a larger infarct volume
(McColl et al., 2007), impairs survival and disrupts BBB (Denes et al., 2011) in experimental
stroke models, through mechanisms that are proposed to involve cytokines.

In the present study, we provide the first evidence that the exacerbation of stroke outcome by a
bacterial infection mimic is due to a novel mechanism of compromised cerebrovascular
endothelial mitochondrial function. Potential deleterious mitochondrial responses to ischemia
have been observed, such as rapid changes in ATP, the release of cytochrome c, and the
induction of the mitochondrial permeability transition (Sims and Anderson, 2002; Sims and
Muyderman, 2010). It is apparent mitochondria play a pivotal role during ischemia; however,
the contributions of mitochondrial dysfunction in non-neuronal cells and the interactions
between these cells and neurons are poorly understood. Additionally, the involvement of
mitochondria in ischemic damage has not been fully elucidated. We show that pharmacological
disruption of endothelial mitochondrial function recapitulates all aspects of the LPS exacerbation
of stroke, including disruption of the BBB, and worsening of stroke outcome. This discovery
could provide a previously unknown mitochondrial-dependent mechanism for acute stroke
damage that may offer new therapeutic directions for the treatment of acute stroke.
3.3. Methods
Mice
All procedures were conducted according to the criteria approved by the Institutional Animal
Care and Use Committees (IACUC) at the West Virginia University (WVU). C57/BL6J male
mice (3-4 months old, 25-30g, Jackson Laboratories) were used for all studies.
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Anesthesia
All surgical anesthesia was induced with 4-5% isoflurane until the animal showed no response to
a toe pinch, and was maintained with 1-2% isoflurane via face-mask in O2-enriched air.

Randomization and blinding of the animal experiments
To assign pre-treatments of mice, we numbered the animals and applied a simple randomization
by using excel-generated random numbers. To avoid biases, we also assured that different pretreatments were performed on the same day. The experimenters were blinded to the pretreatments and data analysis.

Drug administration
In a subgroup of mice, LPS (Escherichia coli 055:B5, 100 μg/kg, Sigma) dissolved in saline (B.
Braun Medical Inc. Irvine, California) was injected intraperitoneally 30 min prior to tMCAO or
sham surgery. In another subgroup of mice, rotenone (1 mg/kg, Sigma) was administered
intraperitoneally 30 min prior to tMCAO. In the EA model, rotenone (2 mg/ml, 2 μl) was
topically applied to the epidural membrane. An equal volume of saline was administered to
control mice.

Ischemic model and sham surgery
We performed focal cerebral ischemia for 30 min or 60 min by occlusion of the right middle
cerebral artery with a 6.0 monofilament suture (Doccol, Sharon, Massachusetts). We used laser
Doppler flowmetry (Moor instruments, United Kingdom) to detect regional cerebral blood flow
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and confirm a successful occlusion (>70% decrease in flow). Rectal body temperature was
maintained at 37 ± 0.5 °C during surgery. Mice were euthanized at several time points as
indicated in the text.

Neurological deficits
Neurologic deficit was determined daily before and after tMCAO according to a 0-5 point scale
neurological score system as published (Harhausen et al., 2010).

Epidural application (EA) model
We induced anesthesia with 4% isofluorane and maintained with 1% isofluorane. We placed the
animal in a prone position under a stereo dissecting microscope and made an incision down the
midline of the head and retracted the skin then removed the fascia from the skull. Using a sharp
blade, we thinned an area of the skull approximately 0.3-0.5 mm in diameter, divided the thinned
area into several segments, performed a craniotomy by gently removing the thinned skull
segments, applied drug or vehicle, and closed the incision.

Exclusion criteria for animal experiments
The exclusion criteria for tMCAO were: 1) regional cerebral blood flow decreases <70% during
occlusion as detected by laser Doppler flowmetry; 2) surgery time lasts more than 30 minutes; 3)
no neurological deficits 3 hour after MCAO (neurological score 0); 4) no infarction in the MCA
territory on TTC staining; 5) subarachnoid hemorrhage on postmortem examination; and 6)
substantial ambient temperature change in the animal facility. Animals which died prior to the
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planned time of assessments were postmortem examined for subarachnoid hemorrhage, and the
mortality was recorded.
The exclusion criteria for EA model were: 1) damaged epidural membrane, 2) bleeding from the
epidural membrane; 3) the leakage of cerebrospinal fluid from the epidural membrane; 4) body
temperature >39.5°C within post-surgery 3 hours; and 5) death.
In this study, 7 mice were excluded: 2 mice (one vehicle and one LPS pre-treatment) because of
subarachnoid hemorrhage, 4 mice (2 vehicle and 2 LPS pre-treatment) because the animal
facility air conditioner broke down on the day that the experiments were performed, 1 mouse
(pre-treated with rotenone) because LDF did not reach 70% reduction during the occlusion. The
animal numbers included in the results are 18 vehicle and 23 LPS for 30 min tMCAO mice (4
LPS pretreated mice died), 12 vehicle and 12 rotenone for 60 min tMCAO mice, 5 vehicle and 5
rotenone for EA mice. No animals were excluded in EA model.

Analysis of brain infarct volume
Mice were euthanized with isofluorane. We removed the brains and cut 2 mm coronal sections
with a mouse brain matrix. We stained the sections with 2% 2,3,5-triphenyltetrazolium chloride
(TTC, Sigma, Saint Louis, Missouri) in phosphate buffer solution (PBS) at 37°C for 30 minutes
then fixed the tissue in 10% formalin phosphate buffer for digital photograph. We analyzed the
digitized image of each brain section using a computerized image analysis software (ImageJ,
NIH) in a double blinded manner. To minimize the effect of brain edema, the volume was
expressed as a percentage of contralateral cortex, striatum, and total hemisphere.
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Blood-brain barrier (BBB) permeability assay in vivo
The permeability of the BBB was determined by measuring the penetration of Evans blue
(Sigma) in the brain tissue. Evans blue (2% in saline, 4 ml/kg body weight) was administered
intravenously via the tail vein one hour prior to measurement. The anesthetized animals were
perfused transcardially with saline before sampling. Each sample was weighed and homogenized
with 400 µl PBS, then precipitated by 50% trichloroacetic acid overnight. The samples were
centrifuged for 30 minutes at 10,000 rpm to pellet brain tissue. Absorption of the supernatant
was measured at a wavelength of 610 nm with a plate reader (BioTek, Winooski, Vermont). The
extravasation of Evans blue was quantified as μg/g brain tissue with an Evans blue standardized
curve.

Isolation of immune cells in the blood, spleen and brain
Blood was collected via cardiac puncture then brain and spleen were sampled after transcardial
perfusion with saline. Peripheral blood mononuclear cells and splenocytes were prepared by
using red cell lysis buffer (eBioscience, San Diego, California). For brain immune cells, the
forebrain was dissected from the cerebellum and suspended in RPMI-1640 medium (Corning,
Pittsburgh, Pennsylvania). The suspension was digested with type IV collagenase (1 mg/ml, MP
Biomedicals, Solon, Ohio) and DNase I (50 μg/ml, Roche Diagnostics, Indianapolis, Indiana) at
37°C for 45 min, then immune cells were isolated by 37–70% Percoll (GE Healthcare,
Piscataway, New Jersey) density gradient centrifugation and collected from the interface. Single
cell suspension was washed with staining buffer (PBS containing 0.1% NaN3 and 2% FCS) and
stained with CD45 (30-F11, eBioscience), CD11b (M1/70, eBioscience), and Gr1 (IA8, BD
Bioscience). Propidium iodide (PI, 2 μg/ml, Sigma) was used to exclude dead cells. Appropriate
66

isotype control antibodies were applied to set quadrants for calculating the percentage of positive
cells. Data were acquired on FACS Calibur (BD) and analyzed with FlowJo software (TreeStar,
Ashland, Oregon).

Cell culture
The bEnd.3 cell line (CRL-2299 from ATCC, Manassas, Virginia) was originally derived from
mouse brain cortex endothelial cells and confirmed by the observed major phenotypic features of
the blood-brain barrier.(Brown et al., 2007a) Passages 25-30 were used in the study. The bEnd.3
cells were routinely grown in high glucose Dulbecco’s modified Eagle’s medium (DMEM,
ATCC) supplemented with 10% FCS and 1% penicillin/streptomycin (Hyclone, South Logan,
Utah) at 37 °C in 5% CO2 humid atmosphere. Mouse primary brain microvascular endothelial
cells (B129-7023 from CellBiologics, Chicago, Illinois) were routinely grown in complete
Endothelial Cell Medium (Cell Biologics, M1168) at 37 °C in 5% CO2 humid atmosphere.

Blood-brain barrier permeability assay in vitro
Permeability assays were performed in triplicate as follows: 1.5×105 endothelial cells were
grown on transwell inserts (pore size: 0.4 mm, diameter: 6.5mm, Millipore, Darmstadt,
Germany) for two days, 250 µg/ml FITC labelled dextran FD-70 (70 kDa, Sigma) was added to
the apical side of the filters and the medium in the basolateral compartment was sampled every
15 min for 2 hours. The FD-70 permeability through the cultured endothelial monolayer was
determined directly by analysis of the apparent permeability coefficient (Papp).(Artursson,
1990) The concentration of FD-70 was determined with an FD-70 standard curve on plate reader
(Ex. 490 nm, Em. 515 nm). Papp (cm/s) was calculated.
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Oxygen Consumption
Oxygen consumption rate (OCR) was measured at 37 °C using an XF96e extracellular analyzer
(Seahorse Bioscience, North Billerica, Massachusetts) according to the manufacturer’s
instructions. Briefly, the bEnd.3 cells or primary endothelial cells were seeded into Seahorse
Bioscience XF96e cell culture plates (16,000 cells/well) in 80 μl medium and allowed to adhere
and grow overnight in the 37 °C humidified incubator with 5% CO2. Then the cells were
supplied with 80 µl medium with or without LPS (concentration varies as indicated in the text)
and cultured for additional 24 hours. For the measurements of extracellular flux, the medium
was changed 1 h prior to the start of the extracellular flux assay to un-buffered (pH 7.4) DMEM
containing 2 mM GlutaMax, 1 mM sodium pyruvate, and 25 mM glucose and incubated at 37 °C
without CO2. Oligomycin, carbonyl cyanide 4-(trifluoromethoxy) phenylhydrazone (FCCP),
rotenone and antimycin A (all from Sigma) and 10× dilutions were prepared for the assays. A
sensor cartridge was loaded with 20 µl of oligomycin (10 µM) into Port A, 20 µl of FCCP (30
µM) into Port B, 20 µl of Rotenone (20 µM) and antimycin A (20 µM) into Port C. The Sensor
cartridge was calibrated and equilibrated and then the protocol was implemented on an XF96e
Analyzer. This protocol allowed determination of the basal level of oxygen consumption, the
amount of oxygen consumption linked to ATP production, the maximal respiration capacity, and
the non-mitochondrial oxygen consumption.

Detect respiratory chain complex I-IV by flow cytometry
We cultured cells in 6 well plates and treated cells with LPS (1 µg/ml) for 48 hours, then we
washed cells and performed intracellular staining with an intracellular staining set (cat. 72-5775,
eBioscience). We stained cells with anti-rabbit-NADH-dehydrogenase-ubiquinone-1-alpha68

subcomplex-assembly-factor-1 (NDUFAF1, sc-292085, 1:100, Santa Crutz), anti-mouseNADH-dehydrogenase-ubiquinone-1-subunit-C2 (NDUFC2, sc-393771, 1:100, Santa Crutz),
anti-mouse-NADH-dehydrogenase-ubiquinone-ironsulfur-protein-2

(NDUFS2,

sc-390596,

1:100, Santa Crutz), anti-rabbit-Succinate-dehydrogenase (SDH, cat.11998, 1:100, Cell
signaling, Beverly, Massachusetts), anti-rabbit-Cytochrome c (Cyc, cat.4280, 1:100, Cell
signaling), anti-mouse-Cytochrome c oxidase (COX IV, cat. 4850, 1:100, Cell signaling)
antibodies for 30 min and labeled the cells with a proper second antibody, PE-anti-rabbit
(Cat.8885, 1:100, Cell signaling) or PE-anti-mouse (Cat.8887, 1:500, Cell signaling).

We

acquired data on BD Calibur flow cytometry and analyzed mean fluorescence intensity by
Flowjo software.

Immunohistochemistry staining
To perform the immunohistochemistry co-staining of mitochondria and MyD88, the bEnd.3 cells
were cultured on cover slips, stained with mitotracker (Life technologies, Grand Island, New
York) for 30 minutes, washed with PBS then fixed with 2% paraformaldehyde (PFA,
Polysciences, Inc.) for 10 minutes at 37 °C. The cells were blocked with 5% goat serum staining
buffer and stained with anti-rabbit-MyD88 (1:200, Abcam, Cambridge, Massachusetts)
overnight, then washed with PBS and stained with goat-anti-rabbit-FITC (Life technologies) for
2 hours. The cells were further washed with PBS and mounted on glass slides using prolong gold
anti-fade reagent (Life technologies). The slides were photographed with confocal LSM 510
microscope Zeiss (Zeiss, Oberkochen, Germany) using software ZEN 2012.
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Statistical Analysis
Statistical analysis was performed with Prism 5 software (Graphpad software, La Jolla,
California). Differences between groups were analyzed by the unpaired Student’s t-test, one way
ANOVA or two way ANOVA as indicated in the figure legends.
3.4. Results
LPS increases cerebral infarction and BBB permeability in stroke
To test the effects of a bacterial infection mimic on stroke outcome, we performed
intraperitoneal (i.p.) injections of LPS (100 µg/kg) or saline 30 minutes prior to a 30-minute
transient middle cerebral artery occlusion (tMCAO) in mice (Fig. 3.1A). LPS challenge
significantly increased infarct volume in the cortex (P = 0.04), striatum (P = 0.009) and total
hemisphere (P = 0.04) after 30 minute tMCAO followed by 48 hour reperfusion (Fig. 3.1B, C).
However, the time course of post-stroke BBB leakage, whether biphasic or progressive, remains
subject to debate (Sandoval and Witt, 2008; Nag et al., 2011). Using Evans Blue as a tracer, our
recent work demonstrated biphasic peaks of BBB openings at 6 hours and 72 hours but not at 24
hours or 48 hours reperfusion following one hour tMCAO (Hu et al., 2014). The 6-hours-peak of
BBB opening may suggest the early inflammatory infiltration and brain edema in acute stroke.
Thus, to determine if the acute infection challenge regulates cerebrovascular response to stroke,
we compared the effects of LPS vs. saline on Evans blue extravasation at 6 hours reperfusion
following tMCAO (Fig. 3.2A). Six hours after tMCAO (30 min occlusion), mice were perfused
and isolated brains were divided into ipsilateral and contralateral hemispheres, and each
hemisphere was analyzed separately for Evans blue extravasation. LPS significantly increased
Evans blue extravasation in the ipsilateral hemisphere after tMCAO compared to control mice
(Fig. 3.2B), indicating that LPS enhances cerebrovascular permeability after stroke.
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LPS increases neutrophil infiltration into the injured brain in stroke
Stroke and acute infections elicit inflammatory responses in the injured brain that are mediated
by multiple factors. Neutrophils are among the first peripheral cells to infiltrate ischemic brain
tissue within 30 minutes to a few hours after focal cerebral ischemia, and neutrophil infiltration
is believed to contribute to acute phase damage in stroke (Gee et al., 2007). To assess brain
leukocyte invasion, we measured neutrophils in brain and peripheral tissues by flow cytometry.
Neutrophil accumulation in the ipsilateral and contralateral brain hemispheres was significantly
greater in the LPS group compared to saline control (n = 5, P < 0.05) at 6 hours tMCAO post
reperfusion (Fig. 3.2C). Concurrently, fewer neutrophils and greater lymphocytes were detected
in the peripheral blood and spleen but monocytes did not differ between vehicle and LPS treated
mice (supplemental Figure 3.1 A, C). The neutrophil to lymphocyte ratio (NLR) was
significantly decreased in the blood (n = 5, P = 0.02), and spleen (n = 5, P = 0.004) of LPStreated mice (supplemental Figure 3.1 B, D). tMCAO mice with LPS exhibited worsened
neurological score at all end point experiments (P = 0.0005, Fig. 3.2D), and mortality was higher
in LPS versus saline tMCAO mice (4/23 vs. 0/18, respectively). Although neutrophil
accumulation in the CNS is complex, these data are consistent with the LPS increased BBB
permeability after tMCAO.

LPS impairs mitochondrial oxidative phosphorylation in CVECs
To determine if the LPS effects in stroke are due to direct effects on cerebrovascular endothelial
cells,

we

employed

a

cultured

cerebrovascular

endothelial

cell

(cCVEC)

model.

Immunohistochemical staining showed that CD31 (an endothelial cell marker) and TLR4 (a LPS
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receptor) colocalize in the brain vasculature (supplemental Figure 3.2 A), closely resembling the
expression of CD31 and TLR4 on cCVECs (supplemental Figure 3.2 B). This indicates that
cCVECs have critical components for an in vitro model to investigate LPS effects on
cerebrovascular endothelial cells.
The brain has a high energy demand and elevated mitochondrial content resulting in it being
vulnerable to reductions in oxidative phosphorylation. Given the expression of TLR4 on the
brain vascular endothelial cells, we determined if LPS would directly affect oxidative
phosphorylation and mitochondrial capacity in CVECs. Using Mitotracker Red for visualization
of mitochondria, we detected MyD88, an adaptor protein involved in TLR4 signaling,(Gay et al.,
2014) broadly distributed but also colocalized with mitochondria in cCVECs (Fig. 3.3A),
suggesting that LPS-induced signaling pathways are linked to mitochondria. To directly evaluate
the mitochondrial function in cCVECs affected by LPS, a bioenergetic assay was used to
examine cellular energetic oxygen consumption rates (OCR). Basal OCR did not significantly
differ in cCVECs challenged by LPS for 24 hours, but maximal respiration and spare capacity
were significantly reduced in cCVECs cultured with 0.1-100 µg/ml LPS (Fig. 3.3B &
supplemental Figure 3.3 A). Similarly, in primary cerebrovascular endothelial cells (pCVECs),
an LPS challenge for 24 hours resulted in a decrease in maximal respiration and spare capacity at
100 μg/ml (Fig. 3.3C & supplemental Figure 3.3B).

However, reduced oxidative

phosphorylation was not associated with cell death or cell viability in cCVECs or pCVECs, as
evidenced by PI staining (supplemental Figure 3.4 A&B), calcein AM staining (supplemental
Figure 3.4 C&D) for 24 hours in the exception of high dose of LPS (100 μg/ml). In view of the
LPS effects on mitochondrial respiration, respiratory chain complex I proteins (NADH
dehydrogenase ubiquinone subunits: NDUFAF1, NDUFS2 and NDUFA2), complex II protein
(Succinate dehydrogenase, SDH), complex III protein (cytochrome c, Cyc), and complex IV
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protein (Cytochrome c oxidase, COX IV) were examined after a 1 μg/ml LPS challenge for 48
hours, and flow cytometry confirmed that LPS decreases the expression of complex I (NDUFS2
and NDUFA2), complex III (Cyc) and complex IV (COX IV) (Fig. 3.3D) proteins. Together
these results strongly suggest that oxidative phosphorylation of CVECs is compromised with
LPS exposure, and this effect does not induce endothelial cell death. As such, we asked if
mitochondrial activity affects endothelial cell function.

Impaired mitochondria disrupt CVEC tight junction and increase BBB permeability
It is known that LPS impairs the BBB permeability both in vitro and in vivo at doses which are
thought to be caused by inflammatory mediators such as cytokines, (Banks and Erickson, 2010)
but little is known about the role of mitochondria in BBB integrity. Using a pharmacological
strategy to manipulate mitochondrial respiration, we first demonstrated that inhibition of
respiratory chain complex I with rotenone (Fig. 3.4A), uncoupling of electron flow from ATP
production with FCCP (Fig. 3.4B), or inhibition of complex V with oligomycin (Fig. 3.4C)
rapidly increased FITC-dextran 70 permeability in a cCVEC monolayer transwell system in
vitro. Immunocytochemical analysis revealed that the normally well-defined, linear cell-cell
junctions were disrupted when oxidative phosphorylation was inhibited by mitochondrial
inhibitors (Fig. 3.4D). Both increased permeability and cell-cell junction disruption due to
inhibition of oxidative phosphorylation occurred in the absence of cell death as evidenced by PI
staining (supplemental Figure 3.5 A) and calcein AM staining (supplemental Figure 3.5 B).
These data suggest for the first time that mitochondria play a key role in maintaining BBB
integrity in vitro.
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To determine if inhibition of mitochondria affects the BBB permeability in vivo, we developed
an epidural application model for CNS drug administration in mice (Fig. 3.5A-D). This model
permits local drug delivery without traumatic brain injury (Fig. 3.5C), thus allowing assessment
of BBB permeability. Rotenone (2µl, 2mg/ml dissolved in saline) was applied to the epidural
surface, and BBB permeability was evaluated by Evans blue quantification after 6 hours. Mice
treated with rotenone showed significantly higher Evans blue extravasation than vehicle controls
(Fig. 3.5D). These data support the hypothesis that mitochondria are critical for the regulation of
cerebrovascular permeability in vivo.

Inhibition of mitochondrial function worsens stroke severity in mice
If inhibition of mitochondrial function increases BBB permeability, the same perturbation would
be expected to affect infarct size and stroke severity. When we treated mice with rotenone prior
to tMCAO (Fig. 3.6A), increased BBB permeability (Fig. 3.6B) and infarct volumes (Fig. 3.6C),
and worsened neurological deficits (Fig. 3.6D) were observed. Thus, the LPS-induced
exacerbation of stroke outcome most likely is due to the deleterious effect of mitochondrial
inhibition.

3.5. Discussion
Acute systemic infection is a risk factor and/or trigger for human stroke (Grau et al., 1995b;
Grau et al., 1995a) and is associated with worsened clinical outcome (Palasik et al., 2005).
Although much is known about the factors that worsen stroke severity in clinical subjects and
experimental stroke models, less is understood about their mechanisms. Our data are the first to
demonstrate that a bacterial infection mimic acts with ischemic challenge to markedly
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exacerbate stroke damage via a mitochondrial-dependent mechanism. This new finding could
also provide an explanation for the association of infections with severity of brain damage and
BBB dysfunction from stroke: the induction of hypometabolism in cerebrovascular endothelial
cell mitochondria.
Mitochondrial dysfunction is increasingly recognized as an accomplice in vascular diseases and
ischemic stroke. More recently, it has been shown that components of the TLR4 signaling
pathways, MyD88 and TRAF6, are linked with mitochondria and affect oxidative
phosphorylation (Kim et al., 2007). The expression of MyD88 in mitochondria of endothelial
cells (Fig. 3.3A) supports that mitochondrial function can be affected by LPS (Fig. 3.3B&C). It
is notable that no significant effect of LPS is seen on cCVEC basal oxygen consumption and
ATP-linked oxygen consumption upon treatment with oligomycin (Fig. 3.3B & supplemental
Figure 3.3), indicating that LPS does not significantly change basal oxygen demand in
mitochondria after 24 hours of treatment with LPS. However, the loss of maximal respiration
and spare capacity (Fig. 3.3B & supplemental Figure 3.3) demonstrates that mitochondrial
capacity is reduced by LPS and thus the effects exacerbate the mitochondrial impairment by
ischemia.

Cellular respiration, mitochondrial biogenesis and function, require coordinated

expression of proteins encoded by nuclear and mitochondrial genes including mitochondrial
complex I-IV. The reduced expression of respiratory chain complex I, III and IV proteins in
cCVECs by LPS provides further evidence that LPS compromises the endothelial mitochondria
function (Fig. 3.3D).

The 30 minute tMCAO model mimics a mild ischemic event that results in a small infarct (Fig.
3.1C) and does not cause visible BBB disruption at 6 hours reperfusion (Fig. 3.2B). The
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bacterial infection mimic challenge prior to tMCAO increased BBB permeability (Fig. 3.2B) and
exacerbated infarct volume (Fig. 3.1C). There are inconsistent data for LPS- or cytokine-induced
BBB dysfunction (Banks and Erickson, 2010) that may be due to complex mechanisms. McColl
et al. (2007) demonstrated an interleukin-1-dependent mechanism of stroke exacerbation using
the same LPS-tMCAO model.

Others have demonstrated that LPS alters transporters or

enzymes involved in BBB maintenance (Banks et al., 2008). Our observation that
pharmacological inhibition of mitochondria disrupts BBB integrity and increases BBB
permeability in vitro (Fig. 3.4) and in vivo (Fig. 3.5) strengthens the argument that BBB
permeability is increased by LPS after stroke (Fig. 3.2) through a direct mitochondrial
mechanism resulting in a larger infarct volume and worsening neurological deficit.

Increased BBB permeability, is positively correlated with massive vasogenic and cytotoxic
edema post-stroke (Taheri et al., 2009; Yang and Rosenberg, 2011) and elevated neutrophils in
the ischemic area that contribute to infarct expansion (Bektas et al., 2010) and poor clinical
outcome (Warach and Latour, 2004). Our observation of neutropenia and low NLR may be a
consequence of BBB damage that causes rapid migration of neutrophils into damaged tissue.
Brain infiltration of neutrophils could also account for secondary lesion growth and increased
infarct size in the ischemic brain as seen with LPS treatment (Fig. 3.1C). These data may
provide translational evidence that neutropenia and low NLR may predict severe stroke.

We observed that LPS-induced inhibition of mitochondria exacerbates infarct volume and opens
BBB in tMCAO mice (Fig. 3.1&3.2), but that mitochondria inhibition in cCVECs and pCVECs
does not affect cell viability in 24 hours (supplemental Figure 3.4). This suggests that the
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functional impairment of endothelial mitochondria by LPS may be reversible and an effective
intervention could be designed to prevent/restore BBB during strokes. However, our data also
indicated that a high dose of LPS (100 μg/ml) induced cell death and reduced cell viability in
cCVECs (supplemental Figure 3.4), and extension of LPS exposure for 48 hours induced cell
death in both cCVECs and pCVECs (supplemental Figure 3.4 A-D). Therefore, the effective
mitochondrial directed intervention may be limited by the severity or the length of the infectious
exposure to rescue BBB damage.

Leukocytosis, and cytokine and chemokine storm are features of the acute-phase reaction in
systemic infections and in acute stroke. It is becoming increasingly apparent that inflammation
can disturb cell energy metabolism.

Our recent study found that neuronal mitochondrial

function was rapidly and profoundly decreased by TNF-α resulting in neuronal cell death (Doll
et al., 2015a). Another study demonstrated that TNF-α elevated oxygen consumption rate in
endothelial cells (Drabarek et al., 2012). The present study did not address the complex LPSinduced effects on mitochondria, however, our novel findings refreshed the traditional idea of
infection-inflammation responses and provided a new explanation for the LPS effects on BBB
dysfunction: a direct mitochondrial-dependent mechanism.

The application of rotenone on the epidural surface argues that its effect on BBB opening is by
compromised mitochondria in vascular endothelial cells (Fig. 3.5). Rotenone exposure is
associated with clinical features of parkinsonism in humans (Tanner et al., 2011), and broadly
used to induce PD like-symptoms in animal models (Chesselet and Richter, 2011) as well. This
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suggests that the mitochondrial-dependent BBB opening may not only involve in the progress of
stroke but also other neurodegenerative disorders such as PD and AD.

In summary, the present study describes a previously unknown mechanism of infection-induced
direct mitochondrial dysfunction in cerebrovascular endothelial cells, which compromises BBB
permeability and exacerbates acute stroke outcomes. Moreover, our observations argue that
maintenance of mitochondrial function is critical to the integrity of the BBB. The data also
suggest a translational significance: maintenance of brain endothelial cell mitochondrial function
can improve the acute outcome of stroke and perhaps other neurodegenerative diseases.
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Figure Legends:
Fig. 3.1. LPS exacerbates stroke infarct volume in mice. (A) Scheme depicting the
experimental design. LPS (100 µg/kg, i.p.) or vehicle (saline, i.p.) was administered 30 min prior
to right transient middle cerebral artery occlusion (tMCAO; 30 min) and 48 hour reperfusion
was performed. (B) Infarct volumes were measured at 48 hours after ischemia induction.
Representative TTC-stained coronal sections used to analyze infarction of mice treated with
vehicle vs. LPS. (C) Mice treated with LPS had significantly larger infarct volume than vehicle
group in cortex, striatum and total hemisphere. Mean ± S.D.; n = 7 per group; Student’s t test. *,
P < 0.05; **, P < 0.01.
Fig. 3.2. LPS increases early BBB leakage and infiltration of neutrophils into the brain of
stroke mice. (A) Scheme of experimental design and workflow. LPS (100 µg/kg, i.p.) or vehicle
(saline, i.p.) was administered 30 min prior to right tMCAO (30 min occlusion) and 6 hour
reperfusion was performed. (B) Evans blue accumulation was visible in the brain of LPS pretreated stroke mice (Red arrows) and quantification of Evans Blue extravasation (µg/g brain
tissue) in contralateral (left) and ipsilateral (right) hemispheres. Vehicle, n = 6; LPS, n = 7. (C)
Representative FACS data for individual hemispheres from mice treated with vehicle vs. LPS
after 30 min tMCAO plus 6 hours reperfusion, and statistical analysis of infiltrated PMNs in the
contralateral (left) and ipsilateral (right) hemispheres measured by FACS. N = 5 per group. (D)
Neurological score at combined two end points (6 hours and 48 hours) after tMCAO. Vehicle, n
= 18, LPS, n = 23. Data are expressed as mean ± S.D.; One-way ANOVA followed by post-hoc
Tukey’s test was used for multiple group comparison and Student’s t test was used for two group
statistical analysis. (**, P < 0.01; ***, P < 0.001; ****, P < 0.0001.)
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Fig. 3.3. LPS reduces mitochondrial function in cultured and primary cerebrovascular
endothelial cells. (A) Immunofluorescence staining of mitochondrial (MitoTracker, purple) costained with MyD88 (green), suggests that the MyD88 expresses on mitochondria of cultured
cerebral vascular endothelial cells (cCVECs). Nuclei were stained with DAPI (blue). Results are
representative from four independent experiments. Images were taken under 63× objective.
Scale bars = 10 μm. (B) Bioenergetics functional assay in cCVECs exposed to various
concentration of LPS compared to vehicle control for 24 hours. Basal respiration, ATP
production, maximal respiration, and spare capacity were calculated from the assay presented in
supplementary Figure 3.3 A. Results are representative from four independent experiments. N =
4 per group; **, P < 0.01; ***, P < 0.001; ****, P < 0.0001 vs. vehicle group. One way
ANOVA followed by post-hoc Tukey’s test was used for data analysis. (C) Bioenergetics
functional assay in pCVECs exposed to various concentration of LPS compared to vehicle
control for 24 hours. Basal respiration, ATP production, maximal respiration, and spare capacity
were calculated from the assay presented in supplementary Figure 3.3 B. Results are
representative from four independent experiments. N = 4 per group; *, P < 0.05 vs. vehicle
group. One way ANOVA followed by post-hoc Tukey’s test was used for data analysis. (D)
Analysis of mitochondrial specific proteins for complex I proteins (NDUFAF1, NDUFS2,
NDUFA2), complex II protein (succinate dehydrogenase, SDH), complex III protein
(cytochrome c, Cyc), and complex IV protein (cytochrome c oxidase, cox IV) in cCVECs after a
1 μg/ml LPS challenge for 48 hours.

Flow cytometry confirmed that LPS decreases the

expression of complex I (NDUFS2 and NDUFA2), complex III (cytochrome c) and complex IV
(cox IV) proteins. Results are representative from three independent experiments. N = 3 per
group; *, P < 0.05; **, P < 0.01; ****, P < 0.0001 vs. vehicle group. Student’s t test was used
for data analysis.
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Fig. 3.4. Pharmacological inhibition of mitochondria increases BBB permeability in vitro.
FITC-Dextran-70 permeability after addition of 20 µM rotenone (A), 20 µM FCCP (B) and 20
µM oligomycin (C) vs. vehicle to cultured cerebrovascular endothelial cells (cCVECs). Data are
presented as both real-time rate of permeability (Two-way ANOVA followed by post-hoc
Dunnett's test) and calculated apparent permeability coefficient (Papp, Student t-test). N = 3 per
group. **, P < 0.01; ***, P < 0.001; ****, P < 0.0001. (D) Confocal fluorescence images of
cCVEC confluent monolayers after treatment with 20 µM rotenone, 20 µM FCCP and 20 µM
oligomycin vs. vehicle for 2 hours. The immunohistochemistry staining of ZO-1 (red) was
performed for tight junctions. Nuclei were stained with DAPI (blue). Mitochondrial inhibitors
apparently disrupted tight junctions and resulted in gaps between cells (white arrows).
Fig. 3.5. Pharmacological inhibition of mitochondria increases BBB permeability in vivo.
(A) Graph depicting the epidural application (EA) model. (B) Exposure of epidural membrane:
vessels were visible under surgical microscope. (C) TTC staining in the EA model showing no
brain injury. (D) Evans blue accumulation was visible in the brain of rotenone applied mice (red
arrows) in EA model and quantitative analysis of Evans blue extravasation (µg/g brain tissue) in
individual brain. N = 5 per group; One-way ANOVA followed by post-hoc Tukey’s test. Data
are expressed as mean ± S.D.; **, P < 0.01.
Fig. 3.6. Impairment of mitochondria function exacerbates stroke outcomes. (A) Scheme of
experimental design and workflow. Rotenone (1mg/kg, i.p.) or vehicle (saline, i.p.) was
administered 30 min prior to right tMCAO (60 min occlusion), BBB permeability was evaluated
at 6 hour reperfusion and infarct volume was measured at 24 hour reperfusion. (B)
Representative brain coronal sections for Evans blue accumulation and quantitative analysis of
Evans Blue extravasation (µg/g brain tissue) in contralateral (left) and ipsilateral (right)
hemispheres. Vehicle, n = 4; Rotenone, n = 4. One-way Data are analyzed with ANOVA
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followed by post-hoc Tukey’s test (*, P < 0.05). (C) Representative TTC-stained coronal
sections used to analyze infarct of tMCAO mice and quantitative analysis of infarct volumes.
Mice treated with rotenone had significant larger infarct volume than vehicle group, in cortex,
striatum, and total hemisphere. Rotenone (1 mg/kg, i.p.) or vehicle (saline, i.p.) was
administered 30 min prior to right tMCAO (1 hour occlusion) and 24 hour reperfusion was
performed. Vehicle, n = 8; Rotenone, n = 8. Data are analyzed with Student’s t tests (**, P <
0.01; ***, P <0.001; ****, P < 0.0001.). (D) Rotenone worsened neurological deficits at 6 and
24 hours after tMCAO. Vehicle, n = 12; Rotenone, n = 12. Data are analyzed with Student’s t
test (****, P < 0.0001).
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Supplemental Materials and Methods:
Cell viability assay
We performed the cell viability assay simultaneously with the oxygen consumption assay. We
seeded cells in 96 black well plates and treated with LPS. We added PI (2 µg/ml) to evaluate
cell death on plate reader (Ex. 535 nm and Em. 617 nm), washed with PBS, added Calcein AM
(Life technology) and stained for 30 minutes to measure cell viability (Ex. 490 nm and Em. 520
nm).

Immunohistochemistry staining
To obtain brain samples for immunohistochemistry assays, animals were anesthetized with
isofluorane and perfused with PBS followed by 10% formalin PBS. Brains were removed, postfixed overnight in 10% formalin PBS at 4°C, cryoprotected in graded sucrose solutions, and
embedded in Tissue-Tek OCT (VWR Scientific). Coronal sections (20 μm) were cut through,
blocked with 5% goat serum staining buffer and stained with rabbit anti-mouse TLR4 (1:100,
Abcam, Cambridge, Massachusetts) and rat anti-mouse CD31 (1:200, Abcam) overnight, and
then washed with PBS and stained with goat-anti-rabbit-FITC and goat-anti-rat-PE antibodies
(Life technologies, Grand Island, New York) for 2 hours. The sections were further washed
with PBS and mounted on glass slides using prolong gold anti-fade reagent (Life
technologies).
To perform the immunohistochemistry staining on bEnd.3 cells, the cells were cultured on
cover slips and fixed with 4% cold paraformaldehyde (PFA, Polysciences, Inc.) followed by
blocking, staining, washing and mounting, as outlined above. The slides or sections were
photographed with confocal LSM 510 microscope Zeiss (Zeiss, Oberkochen, Germany) using
software ZEN 2012.
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Statistical Analysis
Statistical analysis was performed with Prism 5 software (Graphpad software, La Jolla,
California). Differences between groups were analyzed by the unpaired Student’s t-test or one
way ANOVA as indicated in the figure legends.
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Supplemental Figures:

Supplemental Figure 3.1. LPS significantly decreases neutrophils and increases
lymphocytes in peripheral blood and spleen after stroke. Analysis of neutrophils,
monocytes and lymphocytes in blood (A) and spleen (C). Representative FACS data of blood
and spleen showing percentage of Gr1+ polymorphonuclear neutrophils (PMNs), CD11b+Gr1monocytes, and CD11b- Gr1- lymphocytes gated in CD45+ white blood cells (WBCs).
Neutrophil-to-lymphocyte ratio (NLR) in blood (B) and spleen (D). Mice pre-treated with LPS
had significantly fewer neutrophils but more lymphocytes in the blood and spleen than vehicle
group after 30 min tMCAO and 6 hours reperfusion. Data are expressed as mean ± S.D.; n = 5
per group; Student t-test was used for significant analysis, *, P < 0.05; **, P < 0.01.
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Supplemental Figure 3.2. LPS receptor, TLR4, is expressed by endothelial cells in brain
tissue and in culture. (A) Sections from normal mouse brains stained with antibodies to TLR4
(purple) show TLR4 staining in association with CD31 (green), a specific marker for
endothelial cells. (B) Micrographs showing TLR4 (purple) expression in cultured
cerebrovascular endothelial cells (CCVECs, bEnd.3 cell line). Nuclei were stained with DAPI
(blue). Results are representative from four independent experiments. Images were taken under
20× objective. Scale bars, 20 μm.
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Supplemental Figure 3.3. The raw data of oxygen consumption rate determined by the
Seahorse XF96e analyzer. (A) cultured cerebrovascular endothelial cells (cCVECs, bEnd.3
cell line) were incubated with various concentrations of LPS for 24 hours then oxygen
consumption rate (OCR) was determined by the Seahorse XF96e analyzer. (B) Primary
cerebrovascular endothelial cells (pCVECs, originally from adult mouse brain) were incubated
with various concentrations of LPS for 24 hours then OCR was determined by the Seahorse
XF96e analyzer. The mitochondrial inhibitors: oligomycin, FCCP, and rotenone plus antimycin
A were sequentially injected after measurement points 3, 6, and 9 as indicated. Data are
presented as mean ± S.D. at each measurement.
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Supplemental Figure 3.4. LPS and cell viability in cultured cerebrovascular endothelial
cells and primary cerebrovascular endothelial cells. Evaluation of LPS on cell death by
propidium iodide (PI) staining. cCVECs (A) or pCVECs (B) were cultured with LPS (0.01 100 µg/ml) for 24 and 48 hours then stained with PI (2 µg/ml). A microplate reader was
immediately used to determine the mean fluorescent intensity of PI staining. Effect of LPS on
cell viability of cCVECs (C) or pCVECs (D) by calcein-AM staining. After PI staining, cells
were washed with PBS and incubated with calcein-AM (5 µM) for 30 minutes. A microplate
reader was used to determine the mean fluorescent intensity of Calcein AM staining. Data are
presented as mean ± S.D., analyzed by One-way ANOVA followed by post-hoc Tukey’s test.
LPS at 100 µg/ml significantly induced cell death and reduced cell viability in cCVECs after 24
hours culture. *, P<0.05, **, P < 0.01;
****, P < 0.0001.

94

Supplemental Figure 3.5. Mitochondria inhibitors and cell viability in cultured
cerebrovascular endothelial cells at 2 hours. (A) Evaluation of mitochondria inhibitors:
rotenone, FCCP and oligomycin on cell death by propidium iodide (PI) staining in cCVECs.
Confluent cCVEC monolayer were treated with rotenone, FCCP or ologomycin (5 - 80 µM) for
2 hours then stained with PI (2 µg/ml). A microplate reader was immediately used to determine
the mean fluorescent intensity of PI staining. (B) Effects of mitochondria inhibitors on cell
viability by calcein-AM staining. After PI staining, cells were washed with PBS and incubated
with calcein- AM (5 µM) for 30 minutes. Mean fluorescence intensity was determined using a
microplate reader. Data are presented as mean ± S.D., analyzed by One-way ANOVA followed
by post-hoc Tukey’s test. Rotenone at 80 µM significantly reduced cell viability after 2 hours
treatment. Data are presented as mean ± S.D., analyzed by One-way ANOVA followed by posthoc Tukey’s test.
*, P<0.05.
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Behavioral Outcomes
Danielle N. Doll, Elizabeth B. Engler-Chiurazzi, Sara
E. Lewis, Heng Hu, Ashley E. Kerr, Xuefang Ren, and
James W. Simpkins

Doll DN, Engler-Chiurazzi EB, Lewis SE, Hu H, Kerr AE, Ren
X, Simpkins JW. (2015) Lipopolysaccharide Exacerbates Infarct
Size and Results in Worsened Post-Stroke Behavioral
Outcomes. Behavioral and Brain Functions, Under Review.
96

4.1. Abstract
Background: A third of ischemic stroke cases have no traditional underlying causes such as
hypertension, diabetes, atherosclerosis, obesity, or age. Moreover, thirty to forty percent of
strokes occur during or acutely after an active infection and the incidence of stroke increases
during flu season. We and others have shown that the combination of a minor bacterial infection
mimic, 100 μg/kg of lipopolysaccharide (LPS) prior to a minor stroke - 30 minute transient
middle cerebral artery occlusion (tMCAO) - exacerbates infarct volume in a mouse model.
Thus, experimental and epidemiological data strongly suggest that infection and/or inflammation
play a role in stroke occurrence and severity. However, to date, long-term outcomes of stroke
during an active infection has not been studied.
Methods: 3-4 month old C57Bl6/J mice were treated with saline or LPS 30 minutes prior to a
30 minute tMCAO or sham surgery. A behavioral battery was administered to assess health
status/sickness behavior, neurological deficits, motor, cognitive, and affective behaviors.
Results: We show for the first time that exposure to a low dose of LPS prior to a mild stroke
significantly worsens neurological deficits and sickness scores. Motor, cognitive, and affective
behaviors were assessed post-stroke and while stroke significantly affected motor behavior on
rotarod, LPS did not increase the motor deficits. We did not observe any effects of stroke or LPS
on cognitive and affective behaviors.
Conclusions: Our observations of the association between infection, stroke, and worse sickness
and neurological outcomes identify 1) a clinical need to aggressively treat infections in people
with risk factors for stroke and 2) the need to understand the mechanism(s) of the association
between infections and stroke.

97

4.2. Introduction
Stroke is the 5th leading cause of death in the United States and the leading cause of disability
(Lackland et al., 2014). Numerous risk factors such as diabetes, hypertension, and
atherosclerosis have been recognized to increase susceptibility to stroke; however, the
epidemiology of ischemic stroke is not sufficiently explained by the prevalence of these
cerebrovascular risk factors (Grau et al., 1995b). In at least a third of ischemic stroke cases, the
patients lack traditional risk factors and have no apparent cause. The presence of systemic
infection could be an important mediating risk factor. Indeed, thirty to forty percent of strokes
occur during or acutely after an infection (Grau et al., 1995b) suggest an association between
systemic infection and stroke. Although infection has been implicated in increasing
susceptibility to stroke, few studies have examined how an infection prior to stroke affects
outcome. McColl et al. (2007) and Doll et al. (2015c) found that administering
lipopolysaccharide (LPS) 30 minutes prior to transient middle cerebral artery occlusion
(tMCAO) resulted in an increased infarct volume. We have shown that a mechanism by which
lipopolysaccharide (LPS) exacerbates stroke damage involves an increase in blood brain barrier
(BBB) damage through mitochondrial dysfunction (Doll et al., 2015c) and others have suggested
a cytokine-dependent mechanism (McColl et al., 2007). Together, these findings suggest an
association between systemic infection and stroke.

While it is clear that bacterial infection prior to stroke can affect acute stroke damage (McColl et
al., 2007; Doll et al., 2015b), to our knowledge no studies have examined the long-term effects
of a bacterial infection mimic on behavioral outcomes. We hypothesized that LPS administered
prior to stroke would exacerbate the motor, cognitive, and affective behavioral deficits post-
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stroke. To test our hypothesis, we used an animal model of mild infection and mild stroke
developed by McColl et al. (2007), then assessed sickness behavior, neurological deficits,
locomotor, cognitive, and affective behaviors to determine if a bacterial infection can exacerbate
detrimental post-stroke functional outcomes.

4.3. Methods
Subjects
C57/BL6J male mice (3-4 months old, 25-30g, Jackson Laboratories) were used for all studies.
All procedures were conducted according to criteria approved by the Institutional Animal Care
and Use Committees at the West Virginia University.

Randomization and blinding of the animal experiments
To assign groups (Vehicle Sham, LPS Sham, Vehicle Stroke, LPS Stroke), we numbered the
animals and applied a simple randomization by using excel-generated random numbers. To avoid
biases, we also assured that sham and stroke surgeries along with the different treatments (LPS
or vehicle) were performed on the same day. The experimenters were blinded to the pretreatments and data analysis.

Drug administration
LPS (Escherichia coli 055:B5, 100 μg/kg, Sigma) dissolved in saline (B. Braun Medical Inc.
Irvine, California) was administered via an intraperitoneal injection 30 min prior to tMCAO or
sham surgery. An equal volume of saline was administered to vehicle treated mice.
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Ischemic model and sham surgery
We performed focal cerebral ischemia for 30 min by occlusion of the right middle cerebral artery
with a 6.0 monofilament suture (Doccol, Sharon, Massachusetts). All surgical anesthesia was
induced with 4-5% isoflurane until the animal showed no response to a toe pinch, and was
maintained with 1-2% isoflurane via face-mask in O2-enriched air. We used laser Doppler
flowmetry (Moor instruments, United Kingdom) to detect regional cerebral blood flow and
confirm a successful occlusion (>70% decrease in flow). Rectal body temperature was
maintained at 37 ± 0.5 °C during surgery. One cohort of mice was euthanized at 48 hours poststroke to assess infarct area, and a separate cohort was euthanized at the end of the behavioral
battery.

Analysis of brain infarct area-Cohort 1
In one cohort, a total of 28 mice (N=7/group) were euthanized with isoflurane 48 hours postischemia. We removed the brains and cut 2 mm coronal sections with a mouse brain matrix. We
stained the sections with 2% 2,3,5-triphenyltetrazolium chloride (TTC, Sigma, Saint Louis,
Missouri) in phosphate buffer solution (PBS) at 37°C for 30 minutes then fixed the tissue in 10%
formalin phosphate buffer for digital photograph. We analyzed the digitized image of each brain
section using computerized image analysis software (ImageJ, NIH) in a double-blinded manner.
Additional data from this cohort of animals was published in Doll et al. (2015c).
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Behavioral Test Battery-Cohort 2
In another cohort, a total of 40 mice (Vehicle Sham = 10; LPS Sham = 10; Vehicle Stroke = 10;
LPS Stroke = 10) underwent behavioral testing. Two animals were excluded from the LPS stroke
group; one due to post-mortem evidence of cerebral hemorrhage, and a second due to a surgery
complication. The animal excluded due to a surgery complication was replaced resulting in an n
= 9 for the LPS stroke group. The animals were treated and assessed in two cohorts with n = 5 in
each group for each cohort. We selected the following behavioral tests to assess a range of
affective, locomotor, and cognitive abilities and to identify and control for potential locomotor,
visual, or motivational alterations effected by stroke and bacterial infection prior to stroke.
Figure 4.1 depicts the time-course of behavioral testing. All animals underwent the entire test
battery with the exception of Morris water maze. The first cohort showed no significant effects
or trends toward a treatment or surgery effect on this test; thus, we did not subject the second
cohort of animals to Morris water maze testing. However, the timing post-stroke of the other
behavioral assessments were maintained constant across cohorts. All testing was completed
during the light cycle (08:00-15:00) by the same experimenter, who was blind to treatment group
status. Central air conditioning fans provided white noise in the testing room. Between each
animal, the behavior apparatus was cleaned of debris with Virkon and, when appropriate (Open
Field, Elevated Plus Maze), 50% ethanol.

Health and Sickness Behavior Screen
Overall health and sickness behavior was assesses using an objective 20 point screen developed
in our laboratory. The health screen was administered daily by the same experimenter who was
blind to treatment group status. The screen encompasses seven physical domains designed to
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provide insight into the global physical health of an animal. The screen was designed to be rapid
and easy to administer, to be minimally invasive, and to ensure consistency in scoring across the
post-stroke recovery period. To assess health status and sickness behavior, the animal was
observed in its home cage for general appearance, posture, respiration, and spontaneous
locomotion/social interaction. Body condition (emaciation and hydration) was assessed by the
pinch test. Body temperature and body weight were also measured (see supplemental Table 4.1
for scoring criteria). The screen was administered twice prior to tMCAO and each day posttMCAO for 7 days between 0800 and 0930.

Modified Neurological Severity Score (mNSS)
The mNSS, adapted from Chen et al. (2005), assessed neurologic function on a scale of 0 to 12
with 0 being normal and 12 being maximal deficit (see supplemental Table 4.2 for scoring
criteria). The mNSS used here was composed of motor and balance tests; the reflex test was
eliminated due to habituation of the mice after repeat testing. mNSS scores were determined
twice prior to tMCAO and each day post-tMCAO for 7 days between 0800 and 0930.

Cylinder Test
The cylinder test evaluates spontaneous forelimb use and asymmetries resulting from neural
injury(Schaar et al., 2010). The animal was placed in a transparent cylinder (12 cm wide, 19 cm
tall) for 5 minutes and allowed to freely explore. Performance was video recorded for later
assessment. The number of independent wall placements for the right and left forelimbs, in
addition to placement of both forelimbs simultaneously, were recorded. Cylinder test
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performance was conducted twice prior to tMCAO to account for pre-operative handedness
biases, as well as 1, 3, 5 and 7 days post-tMCAO.

Open Field
This task evaluates locomotor activity and emotional reactivity (Denenberg, 1969). A white
plastic box (60 cm x 60 cm x 15 cm) was placed upon a table. Five desk lamps (60 watt each)
provided indirect illumination. At the start of the trial, each mouse was placed in arena at the
midpoint of the South wall and received a 6 minutes session. Locomotor activity was recorded
using Ethovision 8.5 (Noldus Information Technology, Wageningenm, Netherlands). For
analysis, the box floor was divided into inner zone, middle frame, and perimeter zones. The
dependent variables were fecal boli excreted, and distance moved (cm) in the arena as well as
distance moved (cm) in each zone.

Elevated Plus Maze
This task assesses anxiety-like behavior in a novel environment, with mice spending less time in
open arms considered ‘anxious’(Hogg, 1996). Two intersecting arm pairs were arranged in a
‘plus’ configuration and elevated 60 cm from the floor. One arm pair, 58 cm long x 5 cm wide,
was enclosed by walls 15 cm tall and the other arm pair remained open (no walls or edges).
Room illumination consisted of ambient lighting. Each mouse was placed at the arm intersection
point and allowed to freely explore for 5 minutes. The dependent variables were the frequency of
entries into each arm pair, the time spent (s) in the open arm pair, and the number of fecal boli
excreted.
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Visible Platform
This task confirms visual and motor competence for water maze testing (Engler-Chiurazzi et al.,
2012). A circular tub (140 cm in diameter) was filled with clear water. A white- and blackcolored platform with a white/black flag was positioned approximately 0.5 cm above the water
surface in a fixed location within the pool. Blue curtains covered obvious extra maze cues. The
drop-off location varied semi-randomly across trials. Each mouse had 90 sec to locate the
platform, where it remained for 15 sec before being placed back into its heated cage. If an animal
did not locate the platform within the allotted time limit, it was gently guided to the platform.
Between animals, the maze was cleaned of debris and olfactory cues were disrupted using a
fishnet. The inter-trial interval was approximately 12 min. Latency (sec) to reach the platform
was the dependent measure.

Morris Water Maze
Acquisition: The Morris water maze tests hippocampal-dependent spatial reference memory
(Morris et al., 1982), memory for information that remains consistent across time (Olton, 1979).
A round tub (140 cm in diameter) was filled with room temperature water made opaque with
non-toxic paint. Spatial cues (shelving, door, striped posters, etc) were indirectly lit. Briefly, the
mouse was placed in the maze from any of four locations (North, South, East, or West) and had
60 sec to locate a hidden platform submerged 1 cm, which remained in a fixed location
(Northwest quadrant; NW). If an animal failed to locate the platform, it was gently guided to the
platform. After 15 sec on the platform, the mouse was placed into its heated cage until the next
trial. Between animals, the maze was cleaned of debris and olfactory cues. There was
approximately a 15 min inter-trial interval between trials. A tracking system (Ethovision XT 8.5)
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analyzed each mouse’s swim path. Animals received 4 trials for 6 days. The dependent measure
was swim distance (cm). Swim speed (cm/s) was assessed to determine possible locomotor
differences.
Probe Trial: To assess platform localization, on the 6th day of testing an additional probe trial
was given (trial 5), whereby the platform was removed from the maze. Percent of total swim
distance (cm) in the target NW quadrant (i.e., quadrant that once contained the platform) versus
the opposite Southeast (SE) quadrant and frequency of platform zone crossings were the
dependent measure (Stavnezer et al., 2002).
Reversal: To assess cognitive flexibility/perseveration (D'Hooge and De Deyn, 2001), reversal
learning was assessed the following day, whereby the platform was relocated to the SE quadrant.
Animals received 4 trials for 2 days, with a 15 min delay between trials three and four. Trial 5
was a probe trial on day 2. All testing procedures were identical to the Morris water maze
acquisition and probe testing.

Accelerating Rotarod
This task assesses locomotor performance and coordination. A textured plastic horizontal rod (3
cm in diameter) was mounted 14.5 cm above a pressure-sensitive base (Ugo Basile).
Acceleration was set to 4-44 rpm in 300 sec (Jung et al., 2011). For a given trial, a mouse was
placed on the rod and the motor and timer switch were activated. Acceleration continued until
the mouse fell onto the padded base or until 300 sec had elapsed. Animals received 4 trials per
session, with an inter-trial interval of 20 min, and two sessions per day, with an inter-session
interval of 1 hour, for 4 days. Latency to fall (s) was the dependent variable.
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Modified Porsolt Forced Swim Test
This test assesses depressive-like behavioral despair (Cryan et al., 2002). A plastic cylinder (19
cm tall, 12 cm wide) was filled up to a height of 10.5 cm with 25 °C water. Each animal was
tested for 6 minutes. Following each trial, the animal was removed, dried with paper towels, and
warmed in cages heated with a heat pad. The water was changed after each trial. Behavior was
video recorded and quantified by a blind observer who scored each animal as either engaging in
1) active escape behaviors (swimming, climbing, and diving) or 2) immobility (floating or
minimally moving). Behavior of each animal during the first 2 min was not included. Latency (s)
to first immobility, total time (s) spent immobile, and number of fecal boli excreted were the
dependent variables.

Statistical Analysis
Statistical analyses were performed with Statview. Differences between groups were analyzed by
the unpaired Student’s t-test, two-way ANOVA or a repeated measure two-way ANOVA as
appropriate for each outcome measure (indicated in the figure legends).

4.4. Results
Infarct Area
Low dose bacterial infection mimic administered 30 minutes prior to a mild (30 minute) tMCAO
increased cortical infarct area (p < 0.05) and caudate/putamen infarct area (p < 0.05) (Figure
4.2). We measured rectal temperature at 0, 6, 12, 18, 24, and 48 hours post-stroke to ensure that
the increase in infarct volume was not due to an increase in temperature after stroke, and this
data was reported in Doll et al. (2015c) Stroke alone caused a modest decline in rectal
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temperature, while LPS + stroke caused a marked hypothermia post-stroke (Doll et al., 2015c).
These data indicate that the observed increase in infarct volume caused by the combination of
LPS and tMCAO was not due to a febrile response. As such, we then conducted assessments in
an additional cohort of mice for the effects of LPS on the behavioral outcomes of stroke.

Modified Neurological Severity Score
To assess functional neurological damage, the modified neurological severity score (mNSS)
adapted from Chen et al. (2005) was administered for 7 days post-surgery. Prior to surgery, the
mNSS was administered to assess baseline biases, and animals in all 4 groups scored similarly.
Overall there was a Day x Treatment (p = 0.0067) and Day x Surgery interaction (p < 0.0001).
Upon visual inspection of the graph, the stroke and LPS effect diminished over time resulting in
the effect of surgery or treatment being exacerbated in the acute recovery phase (days 1 – 3)
(Figure 4.3), but in the sub-acute recovery phase (days 4 – 6), mNSS scores returned to baseline
levels. This rapid recovery after an insult in mice has been noted previously (Bouet et al., 2007;
Freret et al., 2009). Thus, we blocked the data by acute recovery phase (days 1 – 3) and subacute recovery phase (days 4 – 6) to determine the effect of treatment, surgery, and their
interaction on neurological deficits.

During the first three days post-surgery, there was an

overall Treatment x Surgery interaction (p = 0.0454) indicating that LPS worsens neurological
deficits post-stroke. However, during the sub-acute recovery phase the Treatment x Surgery
interaction was not observed (p = 0.7531), but the Surgery effect remained (p < 0.005).
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Health and Sickness Behavior Screen
Prior to tMCAO (time point 0), the animals in all four groups had a health screen score of 0
indicating that all animals were healthy animals at the time of treatment administration and/or
stroke surgery (Figure 4.4). Overall, there was a Day x Treatment (p < 0.005) and a Day x
Surgery interaction (p < 0.0001). Upon visual inspection of the graph, the surgery and treatment
effects were diminished over time, similarly to the mNSS. Thus, we blocked the data by acute
recovery phase (days 1 – 3) and sub-acute recovery phase (days 4 – 6) to determine the effect of
treatment, surgery, and the interaction on sickness behavior. Overall there were no interactions
between stroke and LPS during the acute or sub-acute recovery phase. During both block of
days there was a significant Surgery effect (p < 0.0001); however, only during the acute phase
was there a significant Treatment effect (p < 0.0005). By the sub-acute recovery, the Treatment
effect diminished (p = 0.0842), but the Surgery effect remained (p < 0.0001).

Motor Function
To assess motor function, performance on the accelerating rotarod was assessed 11 ± 1 days
post-surgery. There was a significant stroke effect resulting in decreased motor function (p <
0.005; Figure 4.5). This effect of stroke surgery on motor function was not due to decreased
locomotor activity because open field indicated no differences between the groups (Table 4.1).
To assess forelimb functional asymmetries, the cylinder task was administered. Before surgery
(Day 0), there were no differences between groups on rearing (Figure 4.6) nor on left versus right
forelimb placement (data not shown). There was an overall Day x Surgery effect (p < 0.0001)
post-surgery (Figure 4.6); thus, we further investigated the effect of surgery on each day. There
was a significant Surgery effect (p < 0.0005) on rearing on Day 1, indicating that animals that

108

had undergone stroke (regardless of drug treatment) were less active than animals who received
sham surgery. By day 3, the surgery effect diminished. This finding of depressed locomotor
behavior (as measured by overall number or rears) limits the interpretation of paw placement
findings.

Affective Behaviors
Stroke nor LPS impacted general locomotor ability nor anxiety-like behavior in the open field
(Table 4.1). There were no significant group differences in distance moved in any zone during
the 6 minute trial (Table 4.1). Similarly, stroke nor LPS impacted anxiety-like behavior on the
elevated plus maze. There were no group differences in the number of open arm entries, number
of closed arm entries, or the time (s) spent in the open arms (data not shown). Moreover, neither
stroke nor LPS impacted depressive-like behavior on the forced swim test. There were no
significant treatment effects on total time spent immobile, or latency to first immobility (data not
shown).

4.5. Discussion
Recent studies have indicated that both Helicobacter pylori (H. pylori) (Wang et al., 2012) and
human cytomegalovirus (HCMV) (Huang et al., 2012) infections are associated with increased
risk for ischemic stroke. Moreover, having a respiratory tract infection increases the risk for an
atherothrombotic ischemic event for up to 3 months (Zurru et al., 2009) and chronic bronchitis
increases risk for stroke and transient ischemic attacks (TIA) (Grau et al., 2009). Lastly,
Grabska et al. (2011) conducted a retrospective chart review of 2066 ischemic stroke patients to
assess the effect of pre-stroke and post-stroke infection on ischemic stroke severity and found
that pre-stroke infection increased poor outcomes within the first 30 days but did not have effects
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at 90 days on modified Rankin scores. From a preclinical perspective, LPS has been shown to
increase infarct volume when administered prior to MCAO in rodents (McColl et al., 2007; Doll
et al., 2015c). However, the long-term effects of stroke during an active infection have not been
studied previously. The present study shows for the first time that low dose LPS increases and
prolongs sickness behavior and worsens neurological deficits post-stroke.

Thus, infection

appears to both trigger and worsen severity of stroke.

It is known that a severe stroke results in motor, cognitive, and affective behavioral deficits
(Markgraf et al., 1994; Rogers et al., 1997; Gibson and Murphy, 2004; Winter et al., 2005; Bouet
et al., 2007). Further, studies have shown that high doses of LPS causes motor, cognitive, and
affective deficits (Dunn and Swiergiel, 2005; De Domenico et al., 2010; Hritcu et al., 2011;
Painsipp et al., 2011; Tarr et al., 2011; Biesmans et al., 2013). However, until the current study,
the long-term functional outcomes of stroke in combination with an active infection had not been
methodically assessed in the rodent model. We hypothesized that the LPS administered prior to
stroke would exacerbate the motor, cognitive, and affective behavioral deficits post-stroke. Our
most robust effects of low dose LPS + mild stroke were on lesion volume, mNSS and sickness.
The hypothermic response to LPS + stroke could be an adaptive protective response, because in
other studies, we observed that maintenance of core body temperature following LPS + stroke
resulted in profound sickness and death of mice (Doll et al., unpublished observations) and that
acute post-stroke hypothermia is strongly associated with larger infarct size in mice (Heng et al.,
unpublished observations). The LPS + stroke effects on mNSS and sickness peaked at one day
after stroke, then recovered over the 7-day observation period, indicating that acute behavioral
response to LPS + stroke is transient, as has been previously reported for stroke alone in rodents
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and humans (Schaar et al., 2010; Grabska et al., 2011). We also showed that stroke, but not LPS
treatment, affects balance and motor coordination during the accelerating rotarod task. As well,
we did not observe effects of stroke, LPS, or their combination on open field, elevated plus maze
or forced swim. Taken together, we demonstrate for the first time that an infection, present at the
time of brain trauma (induced by MCAO) can exacerbate detrimental stroke outcomes,
negatively impacting health and significantly prolonging recovery.

Limitations of the present study are several. We did not observe some of the previously reported
behavioral deficits that have been found following MCAO or LPS among rodents. This is most
likely due to methodological differences between our work and previous studies including 1) the
timing of post-manipulation assessments, 2) the severity of the model of brain insult used here,
and 3) the low dose of LPS used in our study. Indeed, it is well recognized that there are critical
periods for detecting post-stroke deficits (Schaar et al., 2010). As well, many studies assessing
functional outcomes following LPS assessed performance within hours of treatment
administration. Thus, we may have not seen LPS + stroke effects in some behaviors due to the
timing of assessment. Also, severity of the stroke insult may have influenced our ability to
detect functional deficits. Our stroke was a 30 minute tMCAO, which is considered a minor
insult, and caused a small infarct (Figure 2). The low dose of LPS used here, and thus the
severity of the infection induced at the time of stroke also may explain why we did not observe
substantial detrimental behavioral changes. Although others have shown that LPS results in
motor, cognitive, and affective behavioral deficits, the doses used ranged from 0.3 – 10 mg/kg
which are 3 – 100 times higher than the dose used in the present study. Additionally, a few
studies injected LPS multiple times before assessing behavior (Hritcu et al., 2011); thus, the

111

single, low LPS dose given in this study likely resulted in a minor bacterial infection mimic, and
the chosen battery of functional assessments may have not been sensitive enough to detect a mild
impairment at the time points at which they were administered. Future studies should assess
different doses of LPS and determine the time to assess different behavioral deficits.

Furthermore, an increase prevalence of strokes occurs during flu season. Here, we utilized LPS, a
bacterial infection mimic. However, it is not clear whether the exacerbation of post-stroke
functional deficits by LPS found here extend to other types of infection. Thus, the assessment of
the effects of a viral infection mimic prior to stroke on functional outcome is needed.
This study was not designed to assess the mechanism(s) of the interaction between LPS and
stroke, but rather to describe the consequences of this interaction on lesion volume, neurological
deficits, sickness and behavioral outcomes. There are several potential mechanisms by which
LPS could exacerbate stroke outcome. LPS itself is neurotoxic (Lehnardt et al., 2003), and
increases levels of several neurotoxic cytokines, including TNFα (McColl et al., 2007). We have
shown that TNFα causes neuronal loss by inhibition of mitochondrial oxidative phosphorylation
(Doll et al., 2015a). Additionally, LPS compromised the blood-brain barrier (BBB) (Doll et al.,
2015c). As such, through either or both mechanisms, treatment with low doses of LPS may
sensitize animals to the subsequent effects of a mild stroke and thereby worsen outcomes.
Thus, we can conclude from this study that a minor bacterial infection mimic prior to a minor
stroke results in increased infarct area, increased sickness behavior and worse neurological
deficits resulting in delayed functional recovery. Our observations of the association between
infection, stroke, and worse sickness and neurological outcomes argues for the need to
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aggressively treat infection in people with risk factors for stroke and the need to understand the
mechanism(s) of this association.
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Table 4.1: Stroke or LPS does not have an effect on locomotor ability in open field.
Reported are means ± standard error of mean for total distance moved (cm), center duration
(seconds), inner duration (seconds), and outer duration (seconds) during the open field task for
each group.
Total
Center
Inner Duration
Outer
Group
Distance (cm)
Duration (s)
(s)
Duration (s)
Vehicle Sham
2295± 231
5±2
15 ± 3
340 ± 5
LPS Sham
2384 ± 208
5±1
12 ± 3
343 ± 5
Vehicle Stroke
2521 ± 257
5±1
16 ± 5
339 ± 6
LPS Stroke
2553 ± 232
6±1
16 ± 2
338 ± 3
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Figure Legends
Figure 4.1: Timeline schematic of treatment, surgery and behavioral testing.
Figure 4.2: LPS exacerbates infarct area. Cortical and Caudate/Putamen infarct area. A
student’s t-test between control and treatment group showed a significant increase in cortical
infarct area (p = 0.0488) and caudate/putamen infarct area (p = 0.0134). Depicted are mean ±
SEM for 7 mice/group. * p < 0.05
Figure 4.3: Stroke and Stroke + LPS exacerbate neurological deficits. A two way repeated
measures ANOVA showed a significant day by treatment (p = 0.0067) and day by surgery effect
(p < 0.0001). When blocking the data, day 1 – 3 (acute phase recovery) and day 4 – 6 (sub-acute
phase recovery), there was a significant treatment by surgery interaction (0.0454) during the
acute phase of recovery. This significant treatment by surgery interaction was lost during the
sub-acute phase of recovery. Depicted are mean ± SEM for 9 to 10 mice/group. When SEM is
not shown, it is smaller than the symbol used to depict the mean. * p < 0.05
Figure 4.4: Stroke induces sickness behavior. A two way repeated measures ANOVA showed a
significant day by treatment (p = 0.0006) and day by surgery effect (p < 0.0001). When
blocking the data, day 1 – 3 (acute phase recovery) and day 4 – 6 (sub-acute phase recovery,
there was a significant day by surgery effect (p < 0.0001). Depicted are mean ± SEM for 9 to 10
mice/group. When SEM is not shown, it is smaller than the symbol used to depict the mean. ** p
< 0.01; *** p < 0.001
Figure 4.5: Stroke increases motor dysfunction. A two way repeated measures ANOVA showed
a significant surgery effect (p = 0.0011). Depicted are mean ± SEM for 9 to 10 mice/group. **
p < 0.01
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Figure 4.6: Stroke decreases rearing in the cylinder task. A two way repeated measures
ANOVA showed a significant day by surgery effect (p < 0.0001). Further investigation of each
day indicated a significant effect of surgery on day 1 (p = 0.0004) but by day 3 there was no
effect of surgery or treatment. Depicted are mean ± SEM for 9 to 10 mice/group. ** p < 0.01;
*** p < 0.001

116

Figure 4.1
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Figure 4.2
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Figure 4.3
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Figure 4.4
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Figure 4.5
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Figure 4.6
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Supplemental Table 4.1: Health and Sickness Behavior Screen.
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Supplemental Table 4.2: Modified neurological stroke severity score (adapted from Chen
et al., 2005)
Subtest

Score

Walking Test
Normal
Inability to walk straight
Circling toward paretic side
Falling down toward paretic side

3
0
1
2
3

Beam Balance Test
6
Balances steadily or traverses beam to clamp
Grasps sides of beam ( 60 > x > 50 sec)
Hugs beam and/or 1 limb slips/falls down ( 50 > x > 40 sec)
Hugs beam, 2 limbs slip/fall down and/or spins on beam ( 40 > x > 30 sec)
Attempts to balance but very unsteady (30 > x > 20 sec)
Attempts to balance but clings to underside of beam (20 > x > 10 sec)
No attempts to balance and falls ( > 10 sec)

0
1
2
3
4
5
6

Inverted Test
3
Forelimb flexion or limb not moving to aid with balance
1
Hindlimb flexion or limb not moving to aid with balance
1
Head moved more than 10 degrees from vertical center or persistent spin
1
Total = 12
***NOTE for Beam Balance: an animal that balances steadily but falls due to traversing or
exploring the beam should still score close to zero. Similarly, an animal that balances poorly but
stays on for the whole trial should score worse (4-6 range).
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Chapter 5
Discussion
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Discussion
Understanding the role inflammation plays in the etiology and the pathophysiology of stroke is
critical for advancing the field of stroke research. Cytokine production and inflammatory cell
infiltration into the brain post-ischemia has been accepted for years; however, the molecular
mechanisms underlying this immune response are just now being studied. Despite substantial
research and development efforts, there is still only one FDA approved treatment for stroke, tPA.
Previous work has explored several mechanisms of neuroprotection through ion channels,
excitatory amino acids, and oxygen radicals, but none have culminated in an effective
therapeutic effect. Key findings in the field support that inflammatory cells and mediators such
as cytokines are important contributing and confounding factors in ischemic brain injury.
However, our limited understanding of the multi-faceted and complex events of immune
activation following stroke has resulted in many unsuccessful attempts to translate our
knowledge of these key inflammatory mediators into therapies for stroke. Inflammatory
signaling is involved in the damaging events and the tissue repair stages of the ischemic cascade.
Many mediators involved in the ischemic cascade have dual roles; thus, it is important to
understand specific inflammatory mediators that act in spatial and temporal relationships to
develop effective and novel therapeutic strategies. My dissertation focused on one proinflammatory cytokine, TNF-α, which is involved in many co-morbid factors, infection, and
post-stroke inflammation. Although TNF-α is clearly not the only cytokine involved, it has been
correlated with stroke in numerous clinical studies and assessed extensively in animal models.
However, its mechanism of action in neurons at clinically relevant concentrations and exposure
times has not been elucidated.
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TNF-α and mitochondrial function
Our studies show that TNF-α rapidly and profoundly reduces neuronal cell mitochondrial
function. It is widely accepted that mitochondria play a role in neuro-inflammation and
neurodegenerative CNS disorders such as multiple sclerosis, Alzheimer’s disease, and
Parkinson’s disease (Di Filippo et al., 2010). With an insult like ischemic stroke, activation of
microglia occurs that leads to the release of TNF-α along with other pro-inflammatory cytokines
(Davalos et al., 2005). Pro-inflammatory cytokines can activate mitochondria-induced apoptosis
leading to cell death (Huang et al., 2005). Our findings demonstrate that TNF-α exposure caused
neuronal mitochondrial dysfunction as expressed by decreased mitochondrial respiration as early
as 1.5 hours of exposure.

Neurons have a high ATP demand (Zhu et al., 2012), and a temporary reduction in ATP
production results in a profound decrease in neuronal viability (Simpkins et al., 2010). Fiskum et
al. (1999) hypothesized that neuronal death that occurs at the core of an infarct after ischemia
results from the decrease in mitochondrial and glycolytic ATP production. TNF-α is known to
exacerbate infarct size in pre-clinical models of stroke, and this may be due to the profound and
rapid decrease in ATP production, caused by TNF-α release in the evolving ischemic core.
We hypothesized that TNF-α affects mitochondrial function through TNF-R1 because soluble
TNF-α signaling is primarily through TNF-R1 (Wajant et al., 2003; Maddahi et al., 2011).
Blocking TNF-R1 ameliorated the neurotoxic effects of TNF-α on mitochondrial respiration and
cell viability, confirming TNF-α exerts neurotoxic effects through TNF-R1. To further
understand the neurotoxic mechanisms of TNF-α, we assessed caspase 8 and caspase 3/7 activity
because TNF-α can signal through TNF-R1 and activate caspase 8 or caspase 3/7 (Baud and
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Karin, 2001; McCoy and Tansey, 2008). The activation of caspase 8 causes mitochondrialinduced apoptosis through the cleavage of Bcl-2-associated X protein (BAX) and BH3
interacting-domain death agonist (BID) (Aggarwal, 2003; McCoy and Tansey, 2008). Caspase 8
activity was increased in a dose-dependent manner after exposure to TNF-α for 1.5 hours;
however, caspase 3/7 activity was not affected at this early time. The increase in caspase 8
activity led us to hypothesize that mitochondrial membrane potential should decrease if caspase
8 is initiating mitochondrial-induced apoptosis (Green and Kroemer, 2004). The TMRE
mitochondrial membrane potential assay showed a significant dose-dependent decrease in
mitochondrial membrane potential after 1.5 hour of TNF-α exposure. Furthermore, with a
collapse of mitochondrial membrane potential there should be an increase in cytochrome c release
from the mitochondria, due to the cleavage of BAX and BID (Baud and Karin, 2001; Aggarwal,
2003; McCoy and Tansey, 2008). After exposure to 100 pg/ml of TNF-α for 3 and 24 hours,
there was an 11% and 68% increase in cytochrome c release, respectively, from mitochondria.
Our observation of a 19.7% decrease in mitochondrial membrane potential and the 30% decrease
in ATP production at 1.5 hours of treatment with 100 pg/ml TNF-α indicates that sufficient
cytochrome c is released to induce apoptosis (Sas et al., 2007). Once cytochrome c is released,
cytochrome c interacts with apoptotic protease-activating factor-1 (Apaf-1), procaspase-9, and
dATP forming an apoptosome (Sas et al., 2007). The formation of the apoptosome allows for
the activation of caspase-9, which activates procaspase-3, and results in the induction of
apoptosis (Sas et al., 2007).

HT-22 cells and primary mouse cortical neurons both showed a rapid mitochondrial impairment
and subsequent cell death in response to low concentrations of TNF-α. However, there was a
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notable difference between the two cell types in the timing of the TNF-α induced cell death.
Whereas HT-22 cells died within 3 hours of exposure, primary neurons showed cell loss only at
24 hours. The reason for this delayed response of primary neurons is not clear, but is consistent
with the comparative resistance of primary neurons to TNF-α in other studies (Reimann-Philipp
et al., 2001; Zhao et al., 2001). We suspect, but do not have evidence to support, that primary
neurons may have inherent defense mechanisms that resist the neurotoxic effects of a single
cytokine, like TNF-α (Tamatani et al., 1999).

Numerous studies reported an association between increased levels of TNF-α mRNA and protein
and an exacerbation of ischemic injury (Di Filippo et al., 2010). Administration of TNF-αblocking antibodies or soluble TNF-R1 prior to inducing stroke reduces infarct volume
(Murakami et al., 2005; Di Filippo et al., 2010). Our findings may provide the mechanism of
TNF-α exacerbation of stroke damage and shows that TNF-α elicits neurotoxic effects by
inducing a rapid mitochondrial dysfunction mediated through TNF-R1 signaling subsequently
activating caspase 8 and leading to the release of cytochrome c.

Current clinical treatment of ischemic stroke concentrates on dissolving and/or removing the
clot, without much focus on the secondary damage that occurs as part of the inflammatory
ischemic cascade (Works et al., 2013). Inflammation is known to play a major role in the
pathophysiology of stroke and progression of damage post-stroke (Vila et al., 2000a; Iadecola
and Anrather, 2011). The identification of a new therapeutic to reduce brain damage due to
inflammation post-stroke would be clinically useful. However, TNF-α has both pro-apoptotic
and anti-apoptotic activities, and both roles are important physiologically (Aggarwal, 2003).
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When the expression of TNF-α is profound and prolonged, such as after stroke, it has harmful
effects (Aggarwal, 2003). Thus, understanding the neurotoxic mechanism of TNF-α is important
to further advance its potential as a therapeutic target.

As with all in vitro studies, our studies have some limitations, and we interpreted our results with
caution. First, TNF-α was administered at discrete doses (1-1000 pg/ml) for 1.5 to 24 hours.
Post- stroke concentrations change over time and are elevated in patients within 6 hours of
symptom onset and stay elevated for up to 10 days (Zaremba and Losy, 2001; Intiso et al., 2003).
Furthermore, TNF-α mRNA is increased in the ischemic core within 1 hour, and TNF-α
immunoreactive protein is seen within 2-6 hours in the brain after middle cerebral artery
occlusion, (MCAO) in preclinical models (Liu et al., 1994; Botchkina et al., 1997). We observed
mitochondrial impairment with clinically relevant concentrations of TNF-α over a critical time
window post-stroke. An additional limitation is the use of cell culture models such as a
transformed cell line and a primary mouse neuronal culture. Both cell types are models for
neurons, but do not have astrocytes, microglia, or endothelial cells; thus, the results should be
taken with caution. In view of the similarity between the two models, we believe we have
modeled the effects of TNF-α on nerve cells. Finally, we did not evaluate cleavage of BAX and
BID. We assumed the cleavage occurred because caspase 8 cleaves BAX and BID, resulting in
cytochrome c release. Our results support that exposure to TNF-α at 1.5 hours results in an
increase in caspase 8 activity, and by 3 hours we observed a significant release of cytochrome c
from the mitochondria into the cytosol.
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The first part of my dissertation shows, for the first time, a rapid and profound mitochondrial
dysfunction in neurons with acute exposure to low doses of TNF-α. This neurotoxic effect of
TNF-α appears to be mediated by TNF-R1, leading to caspase activation, mitochondrial
membrane potential collapse, and mitochondrial release of cytochrome c. Collectively these data
help to elucidate the neurotoxic mechanisms of TNF-α, and thereby, provides potential targets
for cytokine directed therapy for neuroprotection.

Implications
Post-ischemic inflammation acts through redundant pathways; thus, blocking TNF-α or any one
inflammatory mediator will most likely not be effective. Therapeutic strategies blocking
multiple inflammatory pathways or neutralizing upstream mediators of the ischemic cascade
could be more effective. In experimental models, inhibition of toll like receptors and
complement is highly protective; however, the potential downside of blocking multiple
inflammatory pathways or neutralizing complement or toll like receptors is worsening of
infections after stroke. 30% of patients develop an infection during the acute phase after stroke,
and pneumonia is an independent risk factor for poor outcome and death. Thus, targeting
multiple inflammatory pathways or neutralizing upstream mediators may not be effective
clinically due to increasing the risk in post-stroke infections.

Indeed the intertwined relationship between the immune system and the CNS is complex and not
well understood, but understanding the interaction is essential to harness the full therapeutic
potential of the immunology of stroke. Studying the neurotoxic signaling pathways of specific
inflammatory mediators that have a spatial and temporal effect such as TNF-α, will allow the
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field to develop new therapeutic targets that can target the deleterious effects of the inflammatory
mediator specifically. TNF-α has been shown to participated in stroke initiation, progression of
brain damage acutely post-stroke, tolerance to ischemia, and repair and recovery after stroke as a
mediator and modulator of inflammation. Thus, neutralizing TNF-α with Etanercept or
infliximab, FDA approved anti-TNF therapies, will most likely not be clinically effective
because 1) low blood-brain barrier permeability of the drugs and 2) its role of control and
resolution of inflammation opposing its potent cytotoxicity. Targeting the cytotoxic effect of
TNF-α acutely after ischemia will potentially provide neuroprotection through limiting ischemic
damage while still allowing TNF-α to be a mediator in the repair phase post-stroke. Since we
have shown that TNF-α affects neuronal mitochondrial function, a possible therapeutic
intervention could be increasing mitochondrial function or targeting caspase 8 downstream of
TNF-α signaling to prevent neuronal cell death and limit brain damage.

Moreover atherosclerosis, diabetes, obesity, and infection cause inflammation that contributes to
vascular injury and increases the risk of stroke. TNF-α is an essential cytokine in all of these comorbid factors. Stroke is most commonly caused when an atherosclerotic plaque ruptures, and in
particular, TNF-α plays a key role in not only the development of atherosclerotic plaques but
their destabilization. When monocytes and macrophages were primed and activated to express
high levels of TNF-α when stimulated, rats with no risk factors for stroke were sensitive to
induction of brain ischemia by intraventricular administration of LPS (28). Administration of
recombinant type I soluble TNF receptor prevented these strokes implicating TNF-α as a
necessary causal factor (28). Conventionally, prevention of cerebrovascular disease involve
inhibition of platelet aggregation and the coagulation cascade; however, measures to control the
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TNF-α signaling pathway involved in increasing susceptibility stroke could be used as a
preventive therapeutic.

In support of using TNF-α antagonists or targeting the TNF signaling pathway as a possible
preventive therapeutic for individuals with increased risk for stroke, rheumatic disorders such as
rheumatoid arthritis are characterized with chronic and progressive inflammation similar to many
co-morbid stroke risk factors. TNF-α is a key cytokine in rheumatic disorders, and various TNFα antagonists are used for treatment. A Danish study with 18,247 rheumatoid arthritis patients,
followed for a median of 4.8 years, reported a 30% higher risk of ischemic stroke compared to
those without rheumatoid arthritis (Lindharsen et al., 2012). While traditional stroke risk factors
are more prevalent in patients with rheumatoid arthritis, these factors do not fully explain the
enhanced cerebrovascular risk in this population. Current research in this field suggests that
systemic inflammation is a key player, and rheumatoid arthritis patients taking TNF-α
antagonists had a lower risk for ischemic stroke (Naranjo et al., 2008). However, no randomized
study has corroborated this trend.

TNF-α participates in every facet of stroke: the etiology, pathophysiology, and recovery and
repair phase. The current knowledge of TNF signaling has been studied extensively in nonneuronal cells, and the few studies in neurons use high concentrations and long periods of
exposure. Thus, future studies need to focus on the cooperative role for TNF-α in the complex
ischemic cascade that regulates neuronal life/death decisions and the response of brain cells to
ischemic injury. This improved understanding of TNF mechanism in stroke will improve stroke
treatment and prevention.
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Infection and mitochondrial function
Recent studies have indicated that both Helicobacter pylori (H. pylori) (Wang et al., 2012) and
human cytomegalovirus (HCMV) (Huang et al., 2012) infections are associated with increased
risk for ischemic stroke. Moreover, having a respiratory tract infection increases the risk for an
atherothrombotic ischemic event for up to 3 months (Zurru et al., 2009) and chronic bronchitis
increases risk for stroke and transient ischemic attacks (TIA) (Grau et al., 2009).

Lastly,

Grabska et al. (2011) conducted a retrospective chart review of 2066 ischemic stroke patients to
assess the effect of pre-stroke and post-stroke infection on ischemic stroke severity and found
that pre-stroke infection increased poor outcomes within the first 30 days but did not have effects
at 90 days on modified Rankin scores. Although much is known about the factors that worsen
stroke severity in clinical subjects and experimental stroke models, less is understood about their
mechanisms.

The blood-brain barrier (BBB) is a highly specialized vascular interface that maintains
homeostasis in brain by separating the blood compartment from the central nervous system
(CNS). Disruption of cerebrovascular endothelial cells not only allows entry of unwanted solutes
into brain, but also disrupts the normal CNS entry route of critical nutrients.(Rubin and Staddon,
1999; Gonzalez-Mariscal et al., 2000) The BBB excludes the majority of bacteria; however,
similar to ischemia and reperfusion, inflammation induced by bacteria alters BBB permeability.
Thus far, studies have provided evidence that the release of oxidants, proteolytic enzymes and
inflammatory cytokines alter BBB permeability. Previous studies found that an LPS challenge
results in a larger infarct volume (McColl et al., 2007), impairs survival and disrupts BBB
(Denes et al., 2011) in experimental stroke models, through mechanisms that are proposed to
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involve cytokines. As noted, TNF-α is increased during infections along with other co-morbid
factors that increase risk for stroke, and because we found that TNF-α rapidly and profoundly
decreases mitochondrial function, we hypothesized that the LPS exacerbation of infarct volume
is due decreased endothelial mitochondrial function resulting in increased BBB permeability.
Our data are the first to demonstrate that a bacterial infection mimic acts with ischemic challenge
to markedly exacerbate stroke damage via a mitochondrial-dependent mechanism. This new
finding could also provide an explanation for the association of infections with severity of brain
damage and BBB dysfunction from stroke: the induction of hypometabolism in cerebrovascular
endothelial cell mitochondria.

Mitochondrial dysfunction is increasingly recognized as an accomplice in vascular diseases and
ischemic stroke. More recently, it has been shown that components of the TLR4 signaling
pathways, MyD88 and TRAF6, are linked with mitochondria and affect oxidative
phosphorylation.(Kim et al., 2007). The expression of MyD88 in mitochondria of endothelial
cells supports that mitochondrial function can be affected by LPS. It is notable that we observed
no significant effect of LPS is seen on cCVEC basal oxygen consumption and ATP-linked
oxygen consumption upon treatment with oligomycin, indicating that LPS does not significantly
change basal oxygen demand in mitochondria after 24 hours of treatment. However, the loss of
maximal respiration and spare capacity demonstrates that mitochondrial capacity is reduced by
LPS and thus the effects exacerbate the mitochondrial impairment by ischemia.

Cellular

respiration, mitochondrial biogenesis and function, require coordinated expression of proteins
encoded by nuclear and mitochondrial genes including mitochondrial complex I-IV. The reduced
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expression of respiratory chain complex I, III and IV proteins in cCVECs by LPS provides
further evidence that LPS compromises the endothelial mitochondria function.

The 30 minute tMCAO model mimics a mild ischemic event that results in a small infarct and
does not cause visible BBB disruption at 6 hours reperfusion. The bacterial infection mimic
challenge prior to tMCAO increased BBB permeability and exacerbated infarct volume. There
are inconsistent data for LPS- or cytokine-induced BBB dysfunction (Banks and Erickson, 2010)
that may be due to complex mechanisms. McColl et al.(2007) demonstrated an interleukin-1dependent mechanism of stroke exacerbation using the same LPS-tMCAO model. Others have
demonstrated that LPS alters transporters or enzymes involved in BBB maintenance (Banks et
al., 2008). Our observation that pharmacological inhibition of mitochondria disrupts BBB
integrity and increases BBB permeability in vitro and in vivo strengthens the argument that BBB
permeability is increased by LPS after stroke through a direct mitochondrial mechanism resulting
in a larger infarct volume and worsening neurological deficit.

Increased BBB permeability, is positively correlated with massive vasogenic and cytotoxic
edema post-stroke (Taheri et al., 2009; Yang and Rosenberg, 2011) and elevated neutrophils in
the ischemic area that contribute to infarct expansion (Bektas et al., 2010) and poor clinical
outcome (Warach and Latour, 2004). Our observation of neutropenia and low NLR may be a
consequence of BBB damage that causes rapid migration of neutrophils into damaged tissue.
Brain infiltration of neutrophils could also account for secondary lesion growth and increased
infarct size in the ischemic brain as seen with LPS treatment.

These data may provide

translational evidence that neutropenia and low NLR may predict severe stroke.
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We observed that LPS-induced inhibition of mitochondria exacerbates infarct volume and opens
BBB in tMCAO mice, but that mitochondria inhibition in cCVECs and pCVECs does not affect
cell viability in 24 hours. This suggests that the functional impairment of endothelial
mitochondria by LPS may be reversible and an effective intervention could be designed to
prevent/restore BBB during strokes. However, our data also indicated that a high dose of LPS
(100 μg/ml) induced cell death and reduced cell viability in cCVECs, and extension of LPS
exposure for 48 hours induced cell death in both cCVECs and pCVECs. Therefore, the effective
mitochondrial directed intervention may be limited by the severity or the length of the infectious
exposure to rescue BBB damage.

Leukocytosis, and cytokine and chemokine storm are features of the acute-phase reaction in
systemic infections and in acute stroke. It is becoming increasingly apparent that inflammation
can disturb cell energy metabolism. Our recent study found that neuronal mitochondrial function
was rapidly and profoundly decreased by TNF-α resulting in neuronal cell death (Doll et al.,
2015a). Another study demonstrated that TNF-α elevated oxygen consumption rate in
endothelial cells (Drabarek et al., 2012). The present study did not address the complex LPSinduced effects on mitochondria, however, our novel findings refreshed the traditional idea of
infection-inflammation responses and provided a new explanation for the LPS effects on BBB
dysfunction: a direct mitochondrial-dependent mechanism.

The application of rotenone on the epidural surface argues that its effect on BBB opening is by
compromised mitochondria in vascular endothelial cells. Rotenone exposure is associated with
clinical features of parkinsonism in humans (Tanner et al., 2011), and broadly used to induce PD
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like-symptoms in animal models (Chesselet and Richter, 2011) as well. This suggests that the
mitochondrial-dependent BBB opening may not only involve in the progress of stroke but also
other neurodegenerative disorders such as PD and AD.

In summary, the second part of my dissertation describes a previously unknown mechanism of
infection-induced direct mitochondrial dysfunction in cerebrovascular endothelial cells, which
compromises BBB permeability and exacerbates acute stroke outcomes. Moreover, our
observations argue that maintenance of mitochondrial function is critical to the integrity of the
BBB. The data also suggest a translational significance: maintenance of brain endothelial cell
mitochondrial function can improve the acute outcome of stroke and perhaps other
neurodegenerative diseases.

Statistical Limitation
As with all studies there are limitations such as sample size. When a sample size is small, some
have cautioned against using the t-test. However, De Winter (2010) provided full analysis of
using the Student’s t-test with a small sample size. De Winter (2010) reported that the t-test
provides Type I error rates close to the 5% nominal value in most of the cases (n = 2 ~ 5) and
that acceptable power (80%) is reached only if the effect size is very large. Moreover, William
Sealy Gosset developed the t-test for small sample sizes (Lehmann, 2012). Gosset verified his tdistribution on anthropometric data of 3,000 criminals which he divided into 750 samples each
having an n = 4. It was concluded that there are no principle objections to using a t-test with Ns
as small as 2. We had an n = 3 for each group which was replicated 3 times for the experiment
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testing the effects of LPS on brain endothelial cell mitochondrial function, and we had an n = 3
for the experiment testing the effects of pharmacological inhibition of mitochondria on BBB
permeability. Both of these studies are in vitro studies which by nature are highly homogeneous
resulting in low variances among groups unlike animal and human studies. Thus, a small sample
size is acceptable and routinely used in the field.

Implications
Increased cytokine expression is found centrally and peripherally after ischemic stroke; however,
the evidence for central expression of cytokines has predominately come from experimental
stroke models and for peripheral expression has come from human studies. Thus, this method of
studying cytokines in stroke results in a huge gap in knowledge. Moreover, experimental stroke
studies are invasive and could contribute to the cytokine response confounding our
understanding of the spatial and temporal response of these cytokines. As noted early, TNF-α
has polyphasic roles during ischemia as well as many other of the cytokines. In experimental
stroke studies, TNF-α has been shown to induce preconditioning, increase susceptibility, and be
neuroprotective. Since chronic over expression or chronic deprivation, via receptor knockout, is
not what is endogenously normal, other studies have acutely inhibited TNF-α and showed
neuroprotection. Thus, the next phase of research needs to be the assessment of the roles of
these complex cytokines during stroke to understand the upstream pathways that regulate the
expression of these cytokine and the downstream pathways that amplify inflammation.
There is a general consensus in the field that blocking a single cytokine or inflammatory
mediator will not be an effective therapeutic intervention. Thus, discovering that TNF-α affects
mitochondrial function and that infection prior to ischemia increases BBB permeability through a
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mitochondrial-dependent mechanism suggests that targeting mitochondria could improve stroke
outcome.

Mitochondria are the powerhouses of the cells and involved with oxidative phosphorylation,
calcium homeostasis, reactive oxygen species (ROS) management, and programmed cell death
(Vosler et al., 2009). Disturbing the mitochondrial membrane potential results in caspasedependent and -independent forms of cell death (Taylor et al., 2008; Galluzzi et al., 2009). In
caspase-dependent cell death, cytochrome c release activates the caspase cascade causing
cleavage of numerous proteins and DNA damage (Taylor et al., 2008). In caspase-independent
cell death, calpain - or poly (ADP-ribose) polymerase-1 (PARP1)-mediated apoptosis inducing
factor (AIF) is released from the mitochondria and translocates to the nucleus (Galluzzi et al.
2009). Studies inhibiting these downstream mitochondrial death effectors through inhibition of
caspases, overexpression of X-lined inhibitor of apoptosis (endogenous caspase inhibitor),
HSP70 (binds and sequesters AIF released from the mitochondria), and AIF deletion have shown
neuroprotection acutely post-ischemia (24 hours – 1 week) (Galluzzi et al., 2009; Galluzzi et al.,
2010). Thus, targeting downstream effectors has only short-term protection which is likely due
to the presence of compensatory mechanisms of the mitochondria or to mitochondriaindependent mechanisms like increased oxidative stress.

Since targeting downstream effectors appear to only have short-term protection and the damage
done may be too extensive to reverse, targeting direct effectors of mitochondrial membrane
disruption may be more advantageous. The Bcl-2 family of pro-death proteins (Bax, Bid, Bad,
Bim, and PUMA, among others) are involved with mitochondrial impairment (Youle and
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Strasser, 2008). Bax directly causes mitochondrial membrane disruption through formation of
channels in the outer mitochondrial membrane (Youle and Strasser, 2008). Bid and PUMA aid
Bax channel formation (Youle and Strasser, 2008). While, Bad and Bim inhibit pro-survival
Bcl-2 proteins and Bcl-xL (Youle and Strasser, 2008). Previous work inhibiting pro-death Bcl-2
proteins or increasing pro-survival Bcl-2 proteins has shown neuroprotection (Yin et al., 2006;
Steckley et al., 2007). A single gene deletion of Bax, Bid, Bim, or PUMA only provided limited
neuroprotection, but a triple knockout mouse with deletions of Bax, Bid, and PUMA showed a
prolonged neuroprotection up to 14 days post-ischemia (Vosler et al., 2009). It appears there is a
functional redundancy in pro-death Bcl-2 proteins similar to inflammatory signaling pathways;
thus, targeting a single pro-death Bcl-2 protein similar to targeting one cytokine is not sufficient.
Thus, a potential target that may provide a more robust neuroprotection would be to target
natural inhibitors of the pro-death Bcl-2 proteins, pro-survival Bcl-2 proteins or Bcl-xL.

A more attractive target would be to target further upstream to exert more neuroprotection. MAP
kinase c-Jun N-terminal kinase (JNK) is consistently activated after cerebral-ischemia (Johnson
and Nakamura, 2007). JNK signaling induces programmed cell death in numerous ways; thus, it
has high therapeutic potential. JNK activation directly and indirectly regulates pro-death Bcl-2
family proteins to disrupt mitochondrial membrane potential. JNK phosphorylates the
scaffolding protein that causes release and translocation of Bax to mitochondria, and JNK
phosphorylates Bad and Bim that further activates Bax which inhibits pro-survival Bcl-xL and
Bcl-2 proteins (Gao et al., 2005). In addition, JNK signaling alters the transcription of the
transcription factor c-Jun which promotes up regulation of Fas, Bim, and TNF-α (Mehta et al.,
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2007). Thus, JNK can induce neuronal death through mitochondrial death pathways and by
alteration in the genomic response to shift gene expression toward more pre-death mediators.
It is important to note that JNK is elevated between 0.5 and 24 hours following tMCAO in rats;
thus, clinically targeting JNK would not be limited to a brief time period post-ischemia to exert
its neuroprotective roles (Wang et al., 2007b). Inhibiting JNK using intracerebroventricular
injection of a pharmacological inhibitor SP600125 or a small peptide inhibitor D-JNKI-1 60 or
30 minutes post ischemia, respectively, provides robust neuroprotection (Borsello et al., 2003;
Gao et al., 2005). Moreover, D-JNKI-1 has been administered 6 hours after ischemia and
provided long-lasting neuroprotection and neurobehavioral recovery up to 14 days post-ischemia
(Esneault et al., 2008). In light of this compelling evidence, targeting JNK signaling is an
excellent prospect for clinical neuroprotection.

Lastly, mitochondria are important for cellular homeostasis. Oxidative stress causes extensive
mitochondrial fission which results in neuron death. When the mitochondrial fusion protein
mitofusion 2 is overexpressed, neuronal death can be prevented (Jahani-Asl et al., 2007). This
suggests that tight regulation of fission and fusion is important for neuronal viability. Moreover,
hypoxia increases mitochondrial DNA, total mitochondrial number, expression of mitochondrial
transcription factors, and the mitochondrial protein HSP60 which suggests mitochondrial
biogenesis is an endogenous neuroprotective response (Diaz and Moraes, 2008). After an
ischemic insult mitochondria are damaged and autophagy is induced to remove the damaged
mitochondria. However, neuronal function is dependent on maintenance of energy levels and
cellular homeostasis. Thus, stimulation or enhancement of mitochondrial biogenesis is a novel
therapeutic strategy. More research is needed to understand mitochondrial biogenesis in relation
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to stroke, and future research could focus on the role of alternate transcriptional mechanisms,
mitochondrial fission and fusion mechanisms, and mitochondrial turnover after ischemia to
design new therapeutic targets.

Infection and Post-stroke Outcome
From a preclinical perspective, LPS has been shown to increase infarct volume when
administered prior to MCAO in rodents (McColl et al., 2007; Doll et al., 2015c). However, the
long-term effects of stroke during an active infection have not been studied previously. The last
part of my dissertation shows for the first time that low dose LPS increases and prolongs
sickness behavior and worsens neurological deficits post-stroke.

Thus, infection appears to

both trigger and worsen severity of stroke.

It is known that a severe stroke results in motor, cognitive, and affective behavioral deficits
(Markgraf et al., 1994; Rogers et al., 1997; Gibson and Murphy, 2004; Winter et al., 2005; Bouet
et al., 2007). Further, studies have shown that high doses of LPS causes motor, cognitive, and
affective deficits (Dunn and Swiergiel, 2005; De Domenico et al., 2010; Hritcu et al., 2011;
Painsipp et al., 2011; Tarr et al., 2011; Biesmans et al., 2013). However, until the current study,
the long-term functional outcomes of stroke in combination with an active infection had not been
methodically assessed in the rodent model. We hypothesized that the LPS administered prior to
stroke would exacerbate the motor, cognitive, and affective behavioral deficits post-stroke. Our
most robust effects of low dose LPS + mild stroke were on lesion volume, mNSS and sickness.
The hypothermic response to LPS + stroke could be an adaptive protective response, because in
other studies, we observed that maintenance of core body temperature following LPS + stroke
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resulted in profound sickness and death of mice (Doll et al., unpublished observations) and that
acute post-stroke hypothermia is strongly associated with larger infarct size in mice (Heng et al.,
unpublished observations). The LPS + stroke effects on mNSS and sickness peaked at one day
after stroke, then recovered over the 7-day observation period, indicating that acute behavioral
response to LPS + stroke is transient, as has been previously reported for stroke alone in rodents
and humans (Schaar et al., 2010; Grabska et al., 2011). We also showed that stroke, but not LPS
treatment, affects balance and motor coordination during the accelerating rotarod task. As well,
we did not observe effects of stroke, LPS, or their combination on open field, elevated plus maze
or forced swim. Taken together, we demonstrate for the first time that an infection, present at the
time of brain trauma (induced by MCAO) can exacerbate detrimental stroke outcomes,
negatively impacting health and significantly prolonging recovery.

Limitations of the present study are several. We did not observe some of the previously reported
behavioral deficits that have been found following MCAO or LPS among rodents. This is most
likely due to methodological differences between our work and previous studies including 1) the
timing of post-manipulation assessments, 2) the severity of the model of brain insult used here,
and 3) the low dose of LPS used in our study. Indeed, it is well recognized that there are critical
periods for detecting post-stroke deficits (Schaar et al., 2010). As well, many studies assessing
functional outcomes following LPS assessed performance within hours of treatment
administration. Thus, we may have not seen LPS + stroke effects in some behaviors due to the
timing of assessment. Also, severity of the stroke insult may have influenced our ability to
detect functional deficits. Our stroke was a 30 minute tMCAO, which is considered a minor
insult, and caused a small infarct. The low dose of LPS used here, and thus the severity of the
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infection induced at the time of stroke also may explain why we did not observe substantial
detrimental behavioral changes. Although others have shown that LPS results in motor,
cognitive, and affective behavioral deficits, the doses used ranged from 0.3 – 10 mg/kg which are
3 – 100 times higher than the dose used in the present study. Additionally, a few studies injected
LPS multiple times before assessing behavior (Hritcu et al., 2011); thus, the single, low LPS
dose given in this study likely resulted in a minor bacterial infection mimic, and the chosen
battery of functional assessments may have not been sensitive enough to detect a mild
impairment at the time points at which they were administered. Future studies should assess
different doses of LPS and determine the time to assess different behavioral deficits.
Furthermore, an increase prevalence of strokes occurs during flu season. Here, we utilized LPS, a
bacterial infection mimic. However, it is not clear whether the exacerbation of post-stroke
functional deficits by LPS found here extend to other types of infection. Thus, the assessment of
the effects of a viral infection mimic prior to stroke on functional outcome is needed.
This study was not designed to assess the mechanism(s) of the interaction between LPS and
stroke, but rather to describe the consequences of this interaction on lesion volume, neurological
deficits, sickness and behavioral outcomes. There are several potential mechanisms by which
LPS could exacerbate stroke outcome. LPS itself is neurotoxic (Lehnardt et al., 2003), and
increases levels of several neurotoxic cytokines, including TNFα (McColl et al., 2007). We have
shown that TNFα causes neuronal loss by inhibition of mitochondrial oxidative phosphorylation
(Doll et al., 2015a). Additionally, LPS compromised the blood-brain barrier (BBB) (Doll et al.,
2015c). As such, through either or both mechanisms, treatment with low doses of LPS may
sensitize animals to the subsequent effects of a mild stroke and thereby worsen outcomes.
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Thus, we can conclude from this study that a minor bacterial infection mimic prior to a minor
stroke results in increased infarct area, increased sickness behavior and worse neurological
deficits resulting in delayed functional recovery. Our observations of the association between
infection, stroke, and worse sickness and neurological outcomes argues for the need to
aggressively treat infection in people with risk factors for stroke and the need to understand the
mechanism(s) of this association.

Statistical Interpretation
To simultaneously assess the effects of a minor bacterial infection mimic (LPS) and stroke, we
designed a two x two factorial ANOVA with treatment (LPS or saline) and surgery (tMCAO or
sham) as our independent variables. We performed a two-way repeated measures ANOVA to
assess the effects of stroke and LPS on sickness behavior and neurological deficits. Factorial
designs such as the one implemented here are extremely powerful tools with which “to assess
the generality of a finding by studying the effects of one independent variable under different
conditions, and we evaluate this generality by examining the results of a factorial experiment for
an interaction between the factors”… “An interaction is present when the effects of one
independent variable on behavior change at the different levels of the second independent
variable” (Keppel and Wickens, 194, 201). For sickness behavior, we had a significant Day x
Treatment (p = 0.0006) and Day x Surgery (p < 0.0001) interaction. Thus, we blocked our data
by days 1 – 3 (acute phase post-stroke) and days 4 – 6 (subacute phase post-stroke) to assess the
simple main effects of treatment or surgery in the absence of a significant interaction between
these two independent variables. During the acute phase post-stroke, there was a significant
Treatment effect (p = 0.0005) and Surgery effect (p < 0.0001). However, there was no
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significant Treatment x Surgery interaction (p = 0.3895). This indicates that ignoring whether or
not animals had LPS or saline, animals that underwent tMCAO had increased sickness behavior
as compared to sham animals. Similarly, animals who received LPS had increased sickness
behavior than saline treated animals regardless of surgical status. During the subacute phase, the
Surgery effect remained (p < 0.0001), but there was no significant Treatment effect (p = 0.0842).
We interpreted this data as stroke and LPS affect sickness behavior during the acute phase poststroke, but LPS does not exacerbate the effect of surgery on sickness behavior (no Surgery x
Treatment interaction). For neurological deficit, we had a significant Day x Treatment (p =
0.0067) and Day x Surgery (p < 0.0001) interaction. Thus, we blocked the data similar to
sickness behavior to further probe this interaction. During the acute phase (days 1 – 3), there
was an overall Treatment x Surgery interaction (p = 0.0454) indicating that the effect of LPS
treatment among stroke animals was larger in magnitude than the effect of LPS treatment among
sham animals. Thus, the effect of stroke on neurological deficit was exacerbated by LPS
treatment present at the time of brain injury. During the subacute phase (days 4 – 6), the
Treatment x Surgery interaction was not observed (p = 0.7531), but a main effect of surgery was
observed (p < 0.005). By days 4 – 6, the neurological deficit observed was due to surgery alone.
LPS did not further exacerbate this deficit (p = 0.7531).

Implications
In at least a third of ischemic stroke cases, the patients lack traditional risk factors and have no
apparent cause. These findings and the observation that thirty to forty percent of strokes occurs
during or acutely after an infection (Grau et al., 1995b) suggest an association between systemic
infection and stroke. Although infection has been implicated in increasing susceptibility to
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stroke, few studies have examined how an infection prior to stroke affects post-stroke outcome.
Thus, our findings suggest that an infection prior to stroke increases sickness behavior and
worsens neurological deficits resulting in a delayed functional recovery. These findings should
warrant change in clinical practice.

Currently, individuals with infections are prescribed antibiotics and advised to get rest and drink
fluids. As long as there are no complications, these patients rarely have a follow-up doctor
appointments. Since infection is a risk factor for stroke, populations of individuals that have
other co-morbid stroke risk factors or are at a higher risk for stroke should be monitored by their
family doctors closely during an active infection. Follow-up visits and education about their
increased risk for stroke should be implemented into clinical practice to help prevent stroke.
Although stroke is the leading cause of disability in the United States and is a huge financial
burden, it can be prevented. Thus, clinical practice changes and education are two strategies in
preventing a first stroke which is a major goal of the National Stroke Association.

In addition to infection and other co-morbid factors increasing risk for stroke, after having a
stroke or a transient ischemic attack (TIA), the risk of stroke within 3 months is between 15 –
20% (Wu et al., 2007). Post-stroke, patients have immune suppression. It is thought that this
immune depression is an adaptive response to help prevent autoimmunity against CNS antigens
because studies have correlated the amount of infarcted brain tissue with the concentrations of
CNS antigens (Jauch et al., 2006). Moreover, a Th1 response against these CNS antigens has
been associated with poor 3-month functional outcome (Becker et al., 2011). However, it is
unclear whether this stroke-related autoimmunity to brain antigens is a consequence or a causal
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for post-stroke immune suppression. Another mechanism could be over activation of the
adrenergic system releasing catecholamines and corticosteroids which is supported by increased
serum cortisol and catecholamine levels in patients, and the elevated cortisol levels are an
independent predictor of mortality (Anne et al., 2007). Other studies have shown that depletion
of noradrenergic terminals in the liver or β-adrenergic blockade of these receptors alters cytokine
expression by hepatic invariant Natural Killer cells (iNKT) resulting in decreased immune
suppression, bacterial infections, and decreased mortality in experimental stroke models
suggesting adrenergic nerve terminals in peripheral organs mediate the adrenergic post-stroke
immune suppression (Wong et al., 2011). Although it is unclear the mechanism by which
immune suppression occurs post-stroke, it is known to lead to an increased incidence of
infections post-stroke (Famakin, 2014). Recent studies have shown that up to 30% of stroke
patients have pneumonia or urinary tract infection acutely after stroke, and infections are the
leading cause of death in stroke patients (Westendorp et al., 2011). This increased risk of
infection post-stroke is concerning not only because of its negative impact on outcomes, but the
increased risk of infection could lead to 1) increased susceptibility to a second stroke and 2)
worsen the neurological outcome of a second stroke.

Currently, clinical trials have treated stroke patients prophylactically with antibiotics to prevent
post-stroke infections. The ESPIAS trial had no effect on infection rate or on mortality
(Chamorro et al., 2005). However, the PANTHERIS trial found that infection rate was
decreased but the mortality rate was not significantly affected. The lack of effect on mortality
rate may be due to that the antibiotic treatments are not targeting the endogenous mechanisms
proposed above, autoimmunity to CNS antigens or adrenergic suppression. Moreover,
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prophylactically administering antibiotics pre-stroke in high risk patients or post-stroke could
result in a worse immune suppression complicating post-stroke outcomes further.

Preconditioning in the stroke field is an attractive preventive method for stroke. Preconditioning
is when a sublethal injurious stimulus protects an organ against a subsequent lethal stimulus
(Iadecola and Anrather, 2011). Preconditioning with low doses of LPS, transient non-damaging
ischemic insult to the brain, and administration of recombinant T cell receptor ligand (suppresses
the infiltration of inflammatory cells) provides neuroprotection and protects the brain from
ischemic damage (Subramanian et al., 2009; Bune et al., 2010; Moskowitz et al., 2010; Jensen et
al., 2011). Preconditioning studies have shown that a balance of anti- and pro-inflammatory
mediators is required for the protection because simply suppressing the production of proinflammatory cytokines or the infiltration of inflammatory cells is not effective (Ohtsuki et al.,
1996; Blondeau et al., 2001; Pradillo et al., 2005; Kunz et al., 2007). Thus, prophylactically
treating individuals with antibiotics that are at a high risk for stroke is most likely not a
beneficial preventive method. However, immune modulation pre- and post-stroke has significant
potential. Further understanding of the immunology of stroke is needed and will enable the
development of targeted approaches to selectively suppress the deleterious effects of
inflammation.

Conclusions
My dissertation has provided the field of stroke with the knowledge that TNF-α rapidly and
profoundly decreases mitochondrial function resulting in neuronal cell death and endothelial cell
mitochondrial dysfunction is linked to LPS-induced increased BBB permeability. Moreover, this
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increased BBB permeability by a bacterial infection mimic results in increased ischemic brain
damage and delayed functional recovery post-stroke. My research along with others studying
mechanistically how the immune system and the ischemic brain interacts is essential to guide
therapeutic interventions. Outlined above are various potential therapeutic interventions for
ischemic stroke. I believe that more research should focus on the role of mitochondrial
biogenesis in neurons because stimulation or enhancement of mitochondria is a novel
neuroprotective strategy. Since we show that not only TNF-α exerts its neurotoxicity through
mitochondrial dysfunction but BBB permeability is mediated through mitochondrial dysfunction,
maintenance of mitochondrial biogenesis or targeting mediators of autophagy to enhance the
beneficial effects of mitochondrial preservation may provide neuroprotection at all stages pre and
post-ischemia. The current research suggesting the remarkable impact of modulating the
immune system has on stroke damage and recovery justifies the field’s need to aggressively
pursue basic and clinical studies to elucidate the interaction between the immune and nervous
system pre- and post-stroke. In the near future, tPA will not be the only treatment for stroke.
Strategies to enhance mitochondrial function will be utilized in addition to tPA to improve acute
stroke care.
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Appendix
Table A1: Preliminary assessment of LPS dose and dosing time prior to tMCAO on outcome.
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Figure A1: IL-1 alpha, IL-1beta, IL-2, and IL-4 levels 30 minutes after no (naïve), 100 μg/kg
LPS, or saline (vehicle) injections prior to any surgery. n = 3/group
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Figure A2: IL-6, IL-10, IL-12, and IL-17 alpha levels 30 minutes after no (naïve), 100 μg/kg
LPS, or saline (vehicle) injections prior to any surgery. n = 3/group
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Figure A3: IFN-gamma, TNF-alpha, G-CSF, and GM-CSF levels 30 minutes after no (naïve),
100 μg/kg LPS, or saline (vehicle) injections prior to any surgery. n = 3/group
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